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Microglia, which are the resident immune cells of the central nervous system, 
become activated in response to stress, injury, infection and inflammation. 
Activation of microglia results in excessive production of proinflammatory 
cytokines and neurotoxic factors that underlie several neuropathological 
conditions. Further, the activated microglia undergo morphological 
transformation, rapid proliferation, and directed migration (to the affected region) 
which are regulated by the actin cytoskeleton organization. It was hypothesized 
that genes controlling cytoskeleton organization are involved in microglial 
activation. Determination of factors that inhibit microglial activation has been 
considered to be an important therapeutic strategy for various inflammatory and 
neurodegenerative diseases. 
Dihydropyrimidinase-like 3 (Dpysl3), a member of collapsin response 
mediator protein family, is known to directly regulate the F-actin cytoskeleton. In 
this study, the roles of Dpsyl3 on the inflammatory reaction of activated microglia 
have been investigated. Microarray analysis comparing the global gene expression 
profile of amoeboid and ramified microglia has shown that Dpysl3 is mainly 
expressed in amoeboid microglia in the 5-day postnatal rat brain. 
Immunohistochemical analysis revealed that Dpysl3 was intensely expressed in 
amoeboid microglial cells until postnatal day 7, and then gradually diminished in 
ramified microglia (postnatal day 14). Further, in vitro analysis confirmed that the 
expression of Dpysl3 was induced in activated BV-2 microglial cells by LPS. It is 
well documented that microglial activation increases the expression of iNOS and 
xvi 
 
proinflammatory cytokines through activation of NF-κB activity. In the present 
study, siRNA-mediated knockdown of Dpysl3 prevented the LPS-induced 
expression of iNOS and cytokines including IL-1β, and TNF-α as well as nuclear 
translocation of NF-κB in microglia, indicating that Dpysl3 promotes the 
proinflammatory response of activated microglia.  
Dpysl3 was found to be localized with F-actin cytoskeleton which is 
essential for cell motility and phagocytosis. Knockdown of Dpysl3 inhibited the 
migration and the phagocytic ability of activated microglia coupled with deranged 
actin filament configuration, suggesting that Dpysl3 regulates the microglial 
activation by altering their migration and phagocytic ability through the actin 
cytoskeleton rearrangement. This was further confirmed since the knockdown of 
Dpysl3 attenuated the expression of Rho GTPase cytoskeletal proteins such as 
RhoA and Rac1, which have been shown to regulate inflammatory and oxidative 
responses in activated microglia. 
In summary, the present study demonstrated the mechanism by which 
Dpysl3 regulates the inflammatory response of activated microglia. Dpysl3 is 
developmentally regulated in amoeboid microglia and its expression is increased 
in activated microglial cells. Further, Dpysl3 knockdown in activated microglia 
altered the expression of proinflammatory cytokines such as TNF-α and IL-1β and 
inflammatory mediators including iNOS and NO and the migratory and 
phagocytic ability of activated microglia, possibly by regulating NF-κB and Rho 
GTPase signaling pathways.  
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Overall, this study describes that Dpysl3 not only functions as a 
cytoskeletal gene but also acts as a novel regulator for inflammatory response, 
migration and phagocytosis of activated microglia. Although this study 
demonstrates the potential function of Dpysl3 in activated microglia, further 
studies using in vivo animal models such as Dpysl3 knockout mice and 
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1.1 Central nervous system and its cell types 
The central nervous system (CNS) comprises of the brain and spinal cord which 
contain two main cell types, neurons and the glial cells (Carnevale et al., 2007). 
Glial cells mainly provide support and protection to the neurons. In addition, glial 
cells play essential roles in neuronal development, plasticity and recovery from 
injury (Brown and Neher, 2010).The three main Glial cell types in the central 
nervous system includes microglia, astrocytes and oligodendrocytes (Jessen and 
Mirsky, 1980). 
1.2 Microglia 
Microglia were described as the macrophage-like cells in 1919 by Spanish 
neuroscientist Rio-Hortega (Pessac et al., 2001; Kettenmann et al., 2011). 
Microglia are the  resident immune cells of the CNS, represent approximately 5-
10% of total Glial cell population in the CNS. They respond to injuries and 
infections in the CNS, by producing proinflammatory cytokines and performing 
phagocytosis of cellular debris and pathogens (Guillemin and Brew, 2004; 
Kettenmann et al., 2011).  
 Inflammatory response to injury or stimulation (by a chemical or 
biological agent) in the CNS is a complex process, which initiates a series of 
signaling events. The inflammatory response occurs mainly to remove the 
invading microorganisms as well as the toxic agents thereby resulting in repair 
and healing  (Wyss-Coray and Mucke, 2002; Wyss-Coray, 2006). The process of 





2011).  Microglia have been shown to be ubiquitously distributed throughout the 
CNS and participate in the maintenance of tissue homeostasis by screening the 
brain microenvironment under normal physiological condition (Perry and 
Teeling, 2013). In response to pathological conditions, they undergo rapid 
proliferation resulting in microglosis. Microglia are considered to be both 
detrimental and beneficial in the healthy and diseased CNS (Hanisch and 
Kettenmann, 2007). 
1.3 Morphology of microglia 
Morphologically microglia are classified into 3 phenotypes: amoeboid, ramified 
and reactive. The amoeboid microglia are predominantly found in the developing 
brain and transform into ramified microglia with age. In response to injury or 
inflammation, the ramified microglia transform into reactive which are amoeboid 
in shape (Figure I) (Tambuyzer et al., 2009). 
1.3.1 Amoeboid microglia 
There are several theories on the origin of microglia, the most widely accepted 
theory is that  microglia are derived from circulating mesodermal hematopoietic 
cells which  originate from the yolk sac in mammals (Ling et al., 1991; Kaur et 
al., 2001; Chan et al., 2007). Apart from this theory, studies have also shown that 
blood monocytes enter into the early postnatal brain and transform  into the 
amoeboid microglia (Ling and Wong, 1993). Amoeboid microglia are spherical in 
appearance and function as brain macrophages. They  are  predominantly 





Amoeboid microglia have been shown to have lamellipodia projections  (grooves) 
radiating from its cells body coordinating the direction of migration during 
development (Marin-Teva et al., 1998). In addition, amoeboid microglia are 
involved in phagocytosis of cellular debris/apoptotic cells and also perform 
synaptic pruning during  its development (Zabel and Kirsch, 2013).  
1.3.2 Ramified microglia 
Amoeboid microglia gradually transform into ramified microglia during third 
week of postnatal brain development (Ling and Wong, 1993). Morphologically, 
ramified microglia possess flattened cell bodies and highly branched and long 
processes. They are known to be resting or inactive, while their branches survey 
the microenvironment of the brain (Nimmerjahn et al., 2005). Ramified microglia 
constitute the resident microglial cells that are involved in surveillance of brain 
parenchyma (Aloisi, 2001).  
1.3.3 Activated microglia 
In response to injury or inflammation, the ramified microglia retract its processes 
and transform into activated/reactive microglia. Activated microglia appear as 
large amoeboid shaped cells with enlarged soma and numerous lamellipodia 
which migrate to the site of injury and proliferates to perform strong phagocytic 
activity (Streit et al., 1999; Monif et al., 2009). The function of activated/reactive 
microglia in the brain can be both protective and detrimental. In initial stages of 
neurodegeneration, activated/reactive microglia migrate to the injured site where 





proinflammatory cytokines and nitric oxide factors (Aloisi, 2001). However, 
prolonged microglial activation causes excessive release of proinflammatory 
cytokines and nitric oxide intermediates leading to neuronal death (Kaur and 







Figure I: Diagrammatic representation of different morphology of microglia. 
During brain development, amoeboid microglia transform into ramified 
microglia. In the adult brain, microglia exists in a ramified state. Upon stimuli by 
inflammation or injury, the ramified microglia become hypertrophic and 
transform into a rounded activated phenotype. Adapted and modified from (Streit 
and Xue, 2009; Gomez-Gonzalez and Escobar, 2010). 
1.4 Functions of microglia 
1.4.1 Chemotaxis and migration of microglia 
Activated microglia migrate to the injured site and are involved in phagocytosis of 
cellular debris upon injury in CNS. In addition, microglial migration has also been 
reported during CNS development  (Eyo and Dailey, 2013). Studies have shown 
that migration of microglia towards the injured site in the CNS is regulated by 
Chemokines (Barcia et al., 2012), Rho-family GTPases namely Rho, Rac1, and 
Cdc42 (Saraswathy et al., 2006) and two cytoskeletal proteins namely, actin and 
tubulin. The cytoskeletal proteins namely actin and tubulin are closely associated 





resting condition in vitro, actin and tubulin proteins are confined in the 
perinuclear region. However upon activation by stimulus, the cytoskeletal 
proteins are rearranged to undergo the process of attachment and protrusion 
contributing to microglial migration (abd-el-Basset and Fedoroff, 1995; Eugenin 
et al., 2005). In addition, several factors such as complement proteins, and 
chemokines such as monocyte chemoattractant protein (MCP-1) have been shown 
to stimulate the microglial chemotaxis (Akiyama et al., 1994; Biber et al., 2008; 
Deng et al., 2009). 
1.4.2 Phagocytosis 
Microglia are involved in phagocytosis of apoptotic cells, infectious agents and 
degenerating axons during CNS development and injury (Neumann et al., 2009). 
Light and electron microscopy observations revealed that microglia are 
characterized by cytoplasmic vacuoles and lysosomal bodies that are similar to 
the characteristics of phagocytic cells (Murabe and Sano, 1982; Kaur and You, 
2000). It has been shown that microglia have specific receptor molecules namely 
CR3, immunoglobulin (FcR) and glycation endproducts to facilitate phagocytosis 
(Rotshenker, 2003).  
1.4.3 Proliferation 
Microglial cells undergo rapid proliferation in response to brain injury and 
infection (Kettenmann et al., 2011). Microglial proliferation helps in the repair of 
brain damage and phagocytosis of cellular debris. Microglial proliferation has 





Alzheimer’s disease, and traumatic brain injury (Gomez-Nicola et al., 2013). 
Microglia are induced to proliferate in vitro by several potent molecules like 
interleukin-3 (IL-3), interleukin-6 (IL-6), macrophage colony stimulating factor 
(M-CSF) and granulocyte-macrophage colony stimulating factor granulocyte-
macrophage colony stimulating factor  (GM-CSF) (Lee et al., 1994; Streit et al., 
2000). 
1.4.4 Release of cytokines and reactive oxygen intermediates 
Microglia mediate immune response through the release of cytokines (Hanisch, 
2002). In pathological conditions, the microglia secrete a plethora of cytokines 
that modulate innate defense mechanisms namely nitric oxide (NO) and reactive 
oxygen species (ROS) which are known to be neurotoxic (Smith et al., 2012; di 
Penta et al., 2013).The cytokines secreted by microglia includes proinflammatory 
mediators (namely TNF-α, IL-1β,IL-6) and immunosuppressive cytokine (IL-10). 
In addition, these cytokines modulate the recruitment of leukocytes to CNS and 
involved in tissue repair mechanism (Hanisch, 2002).  
1.4.4.1 Tumor Necrosis Factor-alpha (TNF-α) 
TNF-α is a proinflammatory mediator produced by activated microglia (Figiel, 
2008). TNF-α has been shown to be involved in cell growth, inflammation, 
differentiation and tumorigenesis (Aggarwal et al., 2000). The level of TNF-α 
expression increases rapidly in microglia upon acute insults to the brain and also 
in neurodegenerative disorders namely Parkinson’s disease and Alzheimer’s 





TNF-R2 (Wilt et al., 1995; Cacci et al., 2005). The two receptors differ in their 
expression profiles and downstream signaling. The TNF-R1 contains the death 
domain and this domain is not present in TNF-R2. Binding of TNF-α to TNF-R1 
is responsible for initiation of intracellular signaling namely (MAPK and NF-κB) 
and programmed cell death signaling (Aggarwal et al., 2000; Syed et al., 2007). 
TNF-R2 regulates the expression of anti-inflammatory molecules namely 
granulocyte colony-stimulating factor and IL-10 in microglia (Aggarwal et al., 
2000; Veroni et al., 2010). In addition to this, high levels of TNF-α  has been 
shown to produce toxic effects on  neurons (Couch et al., 2013). In contrast, low 
levels of TNF-α has been shown to be neuroprotective by promoting neural cell 
survival and proliferation (Sriram et al., 2006; Figiel, 2008). 
1.4.4.2 Interleukin 1 beta (IL-1β) 
IL-1β, a member of Interleukin 1 family, is an important cytokine produced by the 
activated microglia (Kim et al., 2006b). IL-1β has been shown to be involved in  
several physiological activities such as cell proliferation, differentiation, apoptosis  
(Sebire et al., 1993), innate defense and immune responses (Netea et al., 2010). 
The expression of IL-1β is upregulated in the activated microglia in response to 
infection, injury or ischemia in the brain and has been linked to the process of 
neuroinflammation and neurodegeneration (Shaftel et al., 2008). IL-1β has been 
reported to bind to type I IL-1 receptor/IL-1 accessory protein complex, leading to 
NFkB-dependent transcription of pro-inflammatory cytokines (TNF-α and IL-6) 
and neutrophil-recruiting chemokines (CXCL1 and CXCL2) in glial cells 





phosphorylation of p38 mitogen activated protein kinase (MAPK). This leads to 
the activation of caspase-3 (Kim et al., 2004; Kim et al., 2006b). Hence, 
suppression of IL-1β has been shown to have neuroprotective effects. 
1.4.4.3 Inducible nitric oxide synthase (iNOS) and Nitric oxide (NO) 
Nitric oxide synthases (NOS) catalyzes the production of nitric oxide (NO) which 
has been shown to modulate microglial activation (Stefano et al., 2004). The NOS 
family consists of 3 isoenzymes namely, neuronal NOS (nNOS), endothelial NOS 
(eNOS), and inducible NOS (iNOS) (Qu et al., 2001). iNOS catalyzes NO 
production in microglia in response to stress (Tran et al., 1997). Activation of 
microglia with LPS in vitro shown to increase the level of iNOS resulting in 
significant amount of NO production (Boje and Arora, 1992). The continuous 
release of NO by activated microglia mediates mitochondrial dysfunction, DNA 
damage and cell death that contribute to neurodegenerative disorders namely 
Alzheimer’s disease, ischemia and Parkinson’s disease (Wyss-Coray, 2006; 
Klegeris et al., 2007). NO  reacts with superoxide and forms peroxynitrite that 
causes cell toxicity (Beckman and Koppenol, 1996).The superoxide is produced 
from mitochondria respiratory chain using variety of enzymes namely, NADPH 
oxidase, cytochromes and P-450 enzymes, xanthine oxidase and iNOS (Wilkinson 
and Landreth, 2006). The activated microglia exhibit increased expression of 
iNOS and NADPH oxidase which are involved in inflammatory processes by 
oxidative stress contributes to the pathogenesis of neurodegenerative diseases 
(Brown, 2007; Brown and Neher, 2010). Combination of NADPH oxidase with 





NO from iNOS expression synergizes with hypoxia and induces neuronal death 
(Park et al., 2002). Further, the NO inhibits cytochrome oxidase resulting in 
glutamate release and excitotoxicity of neurons (Brown and Cooper, 1994; Brown 
and Neher, 2010). This excitotoxicity may be potentiated by a second mechanism 
as NO from iNOS results in glutamate release from astrocytes (Brown and 
Cooper, 1994; Bal-Price and Brown, 2001; Golde et al., 2002). In addition, NO 
secreted by activated microglia leads to the death of oligodendrocytes and impairs 
myelin formation (Miller et al., 2007; Pang et al., 2010). Recently, molecules like 
prostaglandins, FGF, sodium salicylates, glucocorticoids, have been shown to 
attenuate the expression of iNOS thereby controlling amount of NO produced by 
microglia (Kim et al., 1998; Petrova et al., 1999; Arimoto and Bing, 2003). 
1.4.4.4 Generation of Reactive Oxygen Species (ROS) 
Reactive oxygen species (ROS) includes hydroxyl radical (OH•), superoxide 
(O2−), peroxynitrite (ONOO−) and hydrogen peroxide (H2O2), are generated by 
mitochondrial electron transport chain (Inoue et al., 2003) and play important role 
in microglia-mediated neurotoxicity in the neurodegenerative disorders (Uttara et 
al., 2009). Activated microglia produces excessive amount of NADPH oxidase. 
The NADPH oxidase enzyme is a multi-subunit protein complex that reduces 
molecular oxygen to superoxide resulting in generation of ROS. Overproduction 
of ROS leads to oxidative stress to healthy neurons in the vicinity, forming the 
basis for neurodegeneration (Huo et al., 2011; Qin and Crews, 2012). In addition, 
excessive intracellular ROS might result in microglial apoptosis (Block and Hong, 





shown to amplify the secretion of proinflammatory cytokines which trigger the 
activation of several transcription factors (NF-κB) and kinase cascades in age 
related neurodegenerative disorders such as Alzheimer’s disease (Block and 
Hong, 2007).  
1.5 Activation of microglia 
Several studies have described that microglia can be activated in vitro by various 
inflammatory stimuli, such as LPS, beta amyloid (Aβ) to understand the 
molecular mechanisms by which activated microglia mediate neurotoxicity in 
neuropathological conditions.  
1.5.1 Lipopolysaccharide (LPS) 
LPS is a bacterial endotoxin produced from the cell wall of Gram-negative 
bacteria, and has been widely used for microglia activation both in vitro and in 
vivo models (Lund et al., 2006b). Toll-like receptor (TLR)-4 is a receptor/ligand 
for LPS and is expressed by microglial cells (Hines et al., 2013). LPS forms a 
complex with LPS binding protein (LBP) and receptor CD14 for the activation of 
TLR4 signaling. TLR activation is important for mediating immune response 
upon infection. This activation mediates molecular signaling mechanisms namely 
NF-κB, MAPK pathways (Lee et al., 2006) thereby also triggers inflammatory 






1.5.2 Beta –Amyloid (Aβ) 
Aβ is the principle constituent of amyloid plaques, a characteristic feature of 
Alzheimer’s disease (AD). Aβ is commonly used to activate microglial cells in 
vitro (Dheen et al., 2005; Lee and Landreth, 2010; Solito and Sastre, 
2012).Specifically Aβ fragments, Aβ25–35 and Aβ1–42 are used for microglia 
activation (Silei et al., 1999). Microglia interact with Aβ with the help of cell 
surface receptors (namely complement receptors, Fc receptors, toll-like receptors)  
and elicits the activation of signaling cascades thereby resulting in microglial 
activation (Bamberger and Landreth, 2001; Doens and Fernandez, 2014).  
Excessive secretion of proinflammatory cytokines and other molecules, namely 
prostaglandins and chemokines by activated microglia (Fleisher-Berkovich et al., 
2010)  contributes to loss of neurons and cognitive deficits in AD patients (Mrak, 
2012; Rubio-Perez and Morillas-Ruiz, 2012). 
1.6 Signaling pathways involved in microglial activation 
1.6.1 Nuclear factor-κB pathway (NF-κB) 
NF-κB is a key transcription factor that mediates inflammatory response of 
microglia in the CNS (Heese et al., 1998; Caamano and Hunter, 2002; Ghosh and 
Hayden, 2008). NF-κB has been shown to perform various functions in the central 
nervous system. Further, animal models of systemic inflammation have revealed 
the activation of NF-κB in brain tissues (de Mos et al., 2009). In unstimulated 
microglial cells, NF-κB is expressed only in the cytoplasm. Upon activation of 





the transcription of  pro-inflammatory cytokines (TNF-α , IL-1β and IL-6) and 
iNOS (Block and Hong, 2005). 
1.6.2 Mitogen-activated protein kinase pathways (MAPKs) 
MAPKs belong to a highly conserved family serine/threonine  that directs cellular 
responses such as osmotic stress, cell survival, proliferation, apoptosis and 
differentiation (Bachstetter et al., 2011). The MAPK signaling pathway comprises 
of 3 major pathways: (i) p38 MAPK, (ii) extracellular-signal-regulated kinases, 
ERK, (iii) c-Jun N-terminal kinases (JNK). Studies have reported that the MAPK 
pathway is important for microglial activation and mediates the release of the 
proinflammatory cytokines and neurotoxic molecules (Kim et al., 2004; 
Bachstetter et al., 2013). 
Recently, the inhibitors of ERK, p38 MAPK and JNK have been reported  to 
inhibit the microglia activation by reducing the production of a proinflammatory 
cytokines thereby attenuating neuronal cell death (Zhou et al., 2007; Wilms et al., 
2009; Huo et al., 2011). 
1.6.3 Rho family of guanosine triphosphatases GTPases (Rho GTPases) 
Rho GTPases, a small family of signaling G-proteins, mediate intracellular 
signaling cascades such as cell proliferation , apoptosis, actin dynamics and gene 
transcription (Bustelo et al., 2007). The process of cells migration is divided into 
four steps: lamellipodium extension, formation of new adhesions, cell body 
contraction, and tail detachment (Ridley, 2001). The members of Rho GTPases 





of cytoskeleton and causes changes in cell polarity, motility and morphology in 
various cell types including macrophages and neurons (Barcia et al., 2012). The 
activation of these GTPases induces lamellipodia formation by Rac1, filopodia 
formation by Cdc42, actin stress fiber formation by RhoA and focal adhesion 
complex formation by Rac1 and RhoA (Ridley, 2001).Studies have described that 
RhoA pathway has been involved in mediating the inflammatory and oxidative 
responses in microglia (Villar-Cheda et al., 2012). RhoA has been shown to 
regulate phagocytosis, cytokine release, and production of ROS in leukocytes 
(Kitano et al., 2014). Rac1 has been shown to mediate the generation of radicals, 
activation of transcription factors and also induce NADPH oxidase for the 
formation of ROS. Rac1 also seem to be involved in reorganization of actin 
cytoskeleton and phagocytosis plays a key role in microglial activation (Chung et 
al., 2000; Roepstorff et al., 2008). It has been shown that activated Cdc42 and 
Rac1 are localized in the motile cells and initiate the formation of filopodial 
protrusions and lamellipodial extension along the membrane ruffling (Ohsawa et 
al., 2000; Bustelo et al., 2007; Apolloni et al., 2013). Further, the GTPase Rho has 
shown to initiate the formation of actin-myosin filament bundles and focal 
adhesion complexes thereby allowing the attachment of cells to extracellular 
substrates. In neurons and other cell types, Rho GTPases has been shown to 
trigger retraction of neurites and cell rounding (Vincent et al., 2012). 
1.7 Cytoskeleton organization in microglia 
Microglia undergo cellular modeling during migration and phagocytosis (Gitik et 





cytoskeleton and the assembly and disassembly of focal adhesions (Stuart et al., 
2007). Focal adhesions provide structural tethers linking the actin cytoskeleton to 
the extracellular matrix and also serve as a convergence point for signaling 
pathways regulating numerous cellular processes, including migration, 
proliferation, transformation, and apoptosis (Defilippi et al., 2006). For example, 
the scaffolding protein p130Cas is localized in focal adhesions and through its 
multiple interaction domains induces sequential kinase phosphorylation, 
rearrangement of the actin cytoskeleton, and induction of cell migration and 
phagocytosis in microglia (Defilippi et al., 2006; Stuart et al., 2007) . 
 
Figure II: Confocal image show the immunoexpression of F-Actin (red) in 
control and LPS-treated BV-2 microglia. In control BV-2 microglia, F-actin 
filaments are granular in appearance and distributed throughout the cell body. 
Upon activation of microglia (with LPS), the F-actin filaments are organized into 
long microspike projections. 
Microglia comprise of three major cytoskeletal elements: (i) f-actin filaments, (ii) 





the periphery of lamellipodia and they are distributed unevenly throughout the 
cytoplasm of the cell body. The intermediate filaments and microtubules forms 
dense network which radiates to the periphery (Graeber et al., 1988). Activation 
of microglia has been shown to alter the organization of microglial cytoskeleton 
causing F-actin network to reorganize as microspike projections  (Figure II)  (abd-
el-Basset and Fedoroff, 1995). Thus the polymerization and depolymerization of 
actin ﬁlaments is essential for microglial migration and phagocytosis. 
 1.8 Microglial activation in neuropathologies 
Microglial activation is considered as the hallmark of several neurodegenerative 
diseases. 
1.8.1 Microglial activation in Alzheimer’s disease 
Alzheimer’s disease is one of the age-related neurodegenerative disorder 
characterized by memory loss and impairments in cognitive functions (Salawu et 
al., 2011). This disease is characterized by the accumulation of β-amyloid (Aβ) 
and neurofibrillary tangles (NFTs) in the brains thereby resulting in loss of 
neurons and synapses in cortical and subcortical regions (Rogers et al., 2007). 
Studies have shown that microglia play a vital role in clearing the degenerated 
neurons and Aβ plaques in AD (Hickman et al., 2008). However, the continuous 
signals from Aβ peptides and NFTs overactivate microglia which release 
excessive amount of proinflammatory cytokines and neurotoxic molecules, 
thereby resulting in disease progression (Hickman et al., 2008; Crehan et al., 





1.8.2 Microglial activation in Parkinson’s disease 
Parkinson’s disease is a neurological disorder marked by rigidity, tremor and loss 
of postural reflexes. Pathophysiologically, this disease is characterized by loss of 
dopaminergic neurons in the substania nigra pars compacta (SN) with the 
presence of α-synuclein positive lewy bodies within pigmented neurons of 
substania nigra and other parts of brain. α-synuclein is a synaptic vesicle protein, 
a principle element required for the formation of lewy bodies that play essential 
role in both onset and progression of PD (Rogers et al., 2007). Extracellular 
aggregation of α-synuclein induces microglial activation which augments 
neuroinflammation by releasing excessive amount of proinflammatory cytokines 
and neurotoxic molecules, thereby leading to progression of PD (Liu and Hong, 
2003; Croisier et al., 2005; Zhang et al., 2005; Su et al., 2008). This microglial 
activation is characterized by increase in number and changes its morphology to 
an irregular and elongated body and short processes (Richardson and Hossain, 
2013). Increased expression of inducible nitric oxide synthase (iNOS) within the 
SN has been reported in PD patients. Thus, progressive PD is driven by the 
inflammatory response and production of ROS by activated microglia, are 
responsible for loss of dopaminergic neurons in the SN which may play a key role 
in the neurodegeneration (Peterson and Flood, 2012). 
1.8.3 Microglial activation in traumatic brain injury 
Traumatic brain injury (TBI) is an insult to the brain caused by mechanical force 





disruption and the molecules released from injured sites elicit microglial 
activation (Mannix and Whalen, 2012). The activated microglia migrates to the 
injury site and release of proinflammatory cytokines and neurotoxic mediators 
leading to neurotoxicity and neuroinflammation (Ramlackhansingh et al., 2011). 
1.9 Current approaches for controlling microglia activation 
Microglia have been shown to exhibit neuroprotective and neurotoxic functions in 
the CNS (Sawada et al., 2010). Chronic activation of microglia in 
neurodegenerative diseases leads to release of excessive amount of 
proinflammatory mediators and neurotoxic molecules, which further exacerbate 
the neurodegeneration (Kraft and Harry, 2011). Therefore inhibition of microglial 
activation could slow down the process of neurodegeneration and facilitate tissue 
repair aiding in neuron survival and axon regrowth.  Recent studies have 
identified several inhibitors/drugs (such as dexamethasone, retinoic acid etc.) to 
control the activation of microglia (Dheen et al., 2005; Hinkerohe et al., 2010). 
Although these drugs help alleviate the symptoms, their chronic usage leads to 
various side effects. Therefore, identification of novel targets to develop better 
therapeutic strategies for neurodegenerative diseases is required. 
1.10 BV-2 microglial cells for in vitro experimental study  
BV-2 cells are immortalized murine microglial cell line. BV-2 cells have been 
shown to express similar inflammatory gene profile as in vivo microglia upon 
activation.  In addition, BV-2 cells also produce factors and express receptors that 





2009). BV-2 cells  show distinct morphological phenotypes: amoeboid and 
ramified under different culture conditions in vitro (Pottler et al., 2006). The 
primary microglia is more vulnerable to cell toxicity during transfection process 
which led to the replacement with BV-2 microglial cell line for further gene 
functional studies. 
1.11 Global gene expression profiling of microglia 
Global gene expression profiling of amoeboid and ramified microglia were 
performed by isolating the amoeboid and ramified microglia from the corpus 
callosum of 5 days and 28 days rat brains using laser capture microdissection 
(Parakalan et al., 2012). It revealed ~800 genes that were differentially expressed 
between these two groups. The top 25 genes that were highly expressed in 
amoeboid and ramified microglia were obtained based on fold change. Among 
these, Dihydropyrimidinase like 3 (Dpysl3) was found to be highly expressed 
with a fold change of 31.01 in amoeboid microglia when compared to the 






Figure III: Volcano plot represents the differential expression of Dpysl3 in 





microglia and not in ramified microglia. Adapted and modified from (Parakalan 
et al., 2012). 
Dpysl3, also known as Collapsin Response Mediator Protein 4 (Crmp4) 
shown to play significant roles in cytoskeletal rearrangement, axon guidance and 
in semaphorin signaling (Goshima et al., 1995; Quinn et al., 1999). Dpysl3 are 
shown to be expressed in neurons and other glial cells in the brain. However, its 
expression pattern and functional significance in microglia had not been 
elucidated and hence this gene was the focus of this present study. 
1.12 Collapsin Response Mediator Proteins (CRMPs) 
Collapsin Response Mediator Proteins (CRMPs) are cytosolic phosphoproteins 
shown to be widely expressed in the nervous system, and involved in axon 
extension and guidance. CRMPs were first demonstrated as a protein component 
essential for the extracellular Semaphorin signaling (Goshima et al., 1995; Quinn 
et al., 2003). The CRMPs are also termed as the Dihydropyrimidinase related 
proteins (DRPs), turned on after division 64kDa (TOAD64), UNC-33 like 
proteins (Ulip) and TOAD-64/Ulip/CRMP (TUC) proteins  (Goshima et al., 1995; 
Minturn et al., 1995b; Wang and Strittmatter, 1996). CRMPs are composed of 
five members (CRMPs 1-5), among which CRMPs 1-4 share nearly 80% 
homology whereas, CRMP5 shares only 50% homology with the other CRMPs in 
vertebrates  (Goshima et al., 1995; Minturn et al., 1995b; Byk et al., 1996; Wang 
and Strittmatter, 1996). Each CRMP gene is made of 2 isoforms: long CRMP and 





2003; Alabed et al., 2007). In spite of their homology, the physiological roles of 
CRMPs are often diverse in different biological processes. 
1.12.1 Dihydropyrimidinase like-3 (Dpysl3) or Collapsin response mediator 
protein-4 (CRMP4) - Gene Ontology predictions 
The molecular function of Dpysl3 includes SH3 binding domain, chondroitin 
sulfate binding domain (Franken et al., 2003), phosphoprotein binding domain 
and hydrolase activity. In the biological process, Dpysl3 is involved in axon 
guidance for nervous system development (Goshima et al., 1995) and actin 
filament bundle assembly (Rosslenbroich et al., 2005), respond to axon injury 
(Alabed et al., 2007) and pyrimidine nucleobase catabolic process. 
1.13 Expression of Dpysl3 in different cell types 
1.13.1 Dpysl3 in the developing nervous system 
The expression of all Crmps is shown to be differentially regulated in the 
developing rat brain, where the expressions of these genes are high in the first 
postnatal week and then gradually decreased with age (Wang and Strittmatter, 
1996). The expression of Dpysl3/Crmp4 was increased in post mitotic neurons of 
the ventricular zone during corticogenesis and it has been used as a marker for 
cells that undergo neuronal cell fate (Minturn et al., 1995a). In addition, 






1.13.2 Dpysl3 in adult nervous system 
In the adult brain, the expression level of CRMPs is much lower as compared to 
the developing brain except for CRMP2 and CRMP3. The expression level of 
Dpysl3/Crmp4is shown to be increased during neurogenesis in different regions 
of the brain such as hypothalamus, interpeduncular nucleus, cerebral cortex, 
granule cell layer of the cerebellum and visual cortex (Nacher et al., 2000; Liu et 
al., 2003). These regions are important for synaptic rearrangement and axonal 
outgrowth in the adult brain (Nacher et al., 2000). In addition Crmp1, Crmp2, 
Crmp3 and Crmp4/Dpysl3have been shown to be expressed by oligodendrocytes 
of the adult rat brain (Ricard et al., 2000). 
1.13.3 Dpysl3 in the peripheral nervous system 
Apart from the CNS, CRMPs are also highly expressed in neurons of the dorsal 
root ganglion in the peripheral nervous system. Further, Dpysl3/Crmp4 is 
expressed in neuronal cell lines in response to nerve growth factor (NGF) and also 
in dorsal root ganglion by ciliary neurotrophic factor (CNTF) (Byk et al., 1996; 
Jang et al., 2010). 
1.14 Function of CRMPs 
1.14.1 CRMPs in neuronal development 
The CRMPs play functional roles in neuronal migration, neuronal development 
and axonal growth (Charrier et al., 2003). CRMPs help in facilitating the 





inhibiting the collapse of growth cones (Goshima et al., 1995). The Sema3A 
induces the neuronal receptor, Plexin A1 to form a complex with Crmp1 and 
facilitate axonal guidance (Deo et al., 2004). In addition, Crmp2 promotes  axon 
formation  (Inagaki et al., 2001; Yoshimura et al., 2005) whereas, long transcript 
of L-Dpysl3/Crmp4 promotes neurite outgrowth and branching in developing 
cortical neurons and short transcript of S-Dpysl3/Crmp4 promotes axon 
elongation (Quinn et al., 2003; Alabed et al., 2007). Conversely, overexpression 
of Crmp3 and Crmp5 prevents neurite outgrowth (Aylsworth et al., 2009; Brot et 
al., 2010).   
 Crmp1 gene is shown to promote neuronal migration in the cerebral cortex 
(Charrier et al., 2003). Disruption of Crmp1 impairs long-term potentiation (LTP), 
spatial learning and memory that is associated with improper neurite outgrowth 
(Su et al., 2007). Similarly, deletion of Crmp3 leads to abnormal morphogenesis 
of spine and dendrites in the hippocampal neurons resulting in impairment of LTP 
(Quach et al., 2008). 
Further, the CRMPs are also shown to be expressed in oligodendrocytes 
which help in oligodendrocytes outgrowth during the myelination and 
remyelination process (Ricard et al., 2000). 
1.14.2 CRMPs in pathological conditions 
The expression of CRMPs is shown to be highly increased in neuropathological 
conditions such as epilepsy, Huntington’s disease and Alzheimer’s disease (Czech 





antidepressant drugs like tianeptine increases the expression of CRMP-2, while 
other molecules like the epilepsy drug lacosamide and the natural brain 
metabolite lanthionine ketimine bind to CRMP-2 directly and increase its 
neuroprotective effects (Doty et al., 2007; Hensley et al., 2013). These results 
show that altering CRMP expression through pharmaceuticals is possible and 
might help in the protection against various neurological diseases. The 
implication of CRMPs in neuropathological diseases are quite minimal but its 
dysregulation has been widely discussed in cancerous conditions (Gao et al., 
2010b). The implication of CRMPs in these pathological conditions indicates that 
CRMPs are not only involved in the nervous system development (Vuaillat et al., 
2008) and also play wider roles in diverse physiological processes like in 
cancerous events. 
1.15 Signaling pathways involving Dpysl3 
1.15.1 F-actin cytoskeletal bundling 
The interesting feature of CRMPs is their ability to bind with F-actin cytoskeleton 
(Charrier et al., 2003).The interaction of Crmp4 with cytoskeletal proteins like 
tubulin and actin indicates its importance in cell assembly. Among the CRMPs, 
Crmp2 and Crmp4/Dpysl3 are known to directly interact with F-actin 
cytoskeleton and to reorganize the F-actin into tight bundles (Goshima et al., 
1995; Arimura et al., 2005; Rosslenbroich et al., 2005) that are important for 
mediating cell migration. Crmp4/Dpysl3 is shown to localize with F-actin in 





the dorsal root ganglion (Rosslenbroich et al., 2005). Crmp4/Dpysl3 has also been 
shown to colocalized with synaptic vesicle protein2 (SV2) and Intersectin and 
regulate actin dynamics in growth cones (Fulga et al., 2007). Further 
overexpression of Crmp4/Dpysl3 increases the filopodial length and branch in 
neuronal growth cones (Quinn et al., 2003).Thus it is evident that Crmp4/Dpysl3 
can regulate F-actin cytoskeleton and has a broader role in cytoskeletal signaling. 
1.15.2 Rho GTPase Regulators 
The Rho family of guanosine triphosphatases GTPases are small signaling G-
proteins that act as molecular switches and play important role in signaling 
processes such as actin dynamics, cell proliferation, gene transcription and 
apoptosis (Van Aelst and D'Souza-Schorey, 1997). The most widely described 
members of Rho GTPases are Cdc42, Rac1 and RhoA that regulate cytoskeleton 
mechanism (Van Aelst and D'Souza-Schorey, 1997). Studies in non-neuronal 
cells have shown that activation of RhoA, Rac1 or Cdc42 induce the formation of 
lamellipodia and actin stress fibers (Ridley et al., 1992). Indeed, it also regulates 
the cytoskeletal reorganization of growth cone and thereby affects the growth 
cone motility. Further, studies have reported that Rho GTPase regulate several 
physiological processes that are associated with actin cytoskeleton including cell 
migration, wound healing, axon extension, cytokinesis and nerve regeneration 
(Ellezam et al., 2002). The interaction of Crmp4/Dpysl3 with RhoA is shown to 
mediate neurite outgrowth inhibition. This interaction with Rho GTPase activity 






1.16 Role of Dpysl3 in nerve regeneration 
Upon injury in the CNS, the injured axon inhibits regeneration by inhibitory 
signaling molecules. This inhibitory signaling affects the cytoskeleton structure, 
thereby inhibiting growth cone formation and axonal outgrowth (Kalil and Dent, 
2005). CRMPs are shown to be important regulators in mediating nerve 
regeneration. It is shown that RhoA signals through Crmp4/Dpysl3 to inhibit 
neurite outgrowth. Further, blocking the interaction of RhoA-Crmp4/Dpysl3 with 
a C4RIP-V5 construct (CRMP4b (residues 1-126)–RhoA inhibitory peptide fused 
to a V5 epitope tag) has shown to decrease inhibition of neurite outgrowth 
(Alabed et al., 2007; Jang et al., 2010). Overall, it is evident that RhoA-
Crmp4/Dpysl3 interaction pathway is important for cytoskeletal rearrangement 
and Crmp4/Dpysl3 is a critical regulator of axonal outgrowth. 




1.16 Aim of the study 
Microglia transforms into activated state in response to stress, injury, infection 
and cause neurodegeneration in the CNS. The activated microglia undergoes 
morphological transformation, rapid proliferation and directed migration (to the 
affected region) which are related to rearrangements of the actin cytoskeleton. It 
was hypothesized that genes controlling cytoskeleton rearrangement are involved 
in microglial activation. 
Dpysl3 is shown to be directly involved in F-actin bundling 
(Rosslenbroich et al., 2005) and might play an important role in rearrangement of 
microglial actin cytoskeleton during development and activation. The present 
study was aimed at understanding the function of Dpysl3 in microglial activation 
and function. The main objectives of this study are: 
1.16.1 To investigate the expression pattern and function of Dpysl3 in the 
normal or resting and activated microglia 
 The temporal expression pattern of Dpysl3 in microglia in rat brain’s 
corpus collasum in vivo was investigated. 
 The expression pattern of Dpysl3 in activated microglia (by LPS) in vivo 
and in vitro was investigated. 
  The role of Dpysl3 in the production of proinflammatory cytokines by 
activated microglia was studied. Specifically, effects of siRNA-mediated 
knockdown of Dpysl3 in control and activated BV-2 microglia on the 
expression and production of proinflammatory cytokines were examined. 




1.16.2 To examine the role of Dpysl3 in microglial migration, phagocytosis 
and proliferation 
The transformation from resting to activated state of microglia induces changes in 
their morphology, migratory behavior, cytoplasmic motility, phagocytic ability. It 
has been studied that the changes in cell morphology and activity are 
accompanied by the changes involved in organization of cytoskeleton and also the 
expression of different cytoskeletal proteins in microglia. It was hypothesized that 
Dpysl3, known to regulate F-actin (Rosslenbroich et al., 2005), cytokinesis and 
cytoskeleton formation during development, may regulate microglial activation. 
To address this, 
 Effects of siRNA-mediated knockdown of Dpysl3 on migration, 
phagocytosis and proliferation of activated BV-2 microglia were 
examined. 
1.16.3 To examine the role of Dpysl3 in cytoskeleton organization of activated 
microglia 
Activation of microglia is associated with changes in cytoskeletal organization. 
Dpysl3 is shown to regulate the F-actin cytoskeleton causing changes in the 
migration activity of other cell types such as neurons cells (Rosslenbroich et al., 
2005). The regulatory molecules involved in cytoskeletal organization in 
microglia had not been elucidated. To address this, 
 The co-localization of Dpysl3 with F-actin cytoskeleton in activated 
microglia was confirmed. 




 Effects of siRNA-mediated knockdown of Dpysl3 on F-actin bundling and 
microspike projection in activated microglia were investigated. 
1.16.4  To investigate the role of Dpysl3 in Rho GTPases cytoskeletal 
pathway 
Dpysl3 is shown to interact with Rho GTPases (RhoA and Rac1), which are 
required for cytoskeletal organization for cell migration (Van Aelst and D'Souza-
Schorey, 1997; Yoshimura et al., 2005; Villar-Cheda et al., 2012). The RhoA and 
Rac1 pathways have been shown to regulate inflammatory and oxidative 
responses in microglia (Van Aelst and D'Souza-Schorey, 1997). The interaction 
of Dpysl3 with cytoskeletal proteins, RhoA and Rac1 have not been elucidated in 
microglia. To address this 
 Effects of siRNA-mediated knockdown of Dpysl3 on the expression of 
RhoA and Rac1 in activated microglia were investigated.  
The findings of this study will provide novel insights into the regulatory 
mechanism by which the cytoskeletal proteins contribute to microglia activation 




































Wistar rats aged 5, 7, 14 and 28 days were used in this study. The rats were 
obtained from Laboratory Animal Centre, National University of Singapore. 
Animal handling and experimental procedures were performed under the 
guidelines set by Institutional Animal Care and Use Committee (IACUC), 
National University of Singapore (IACUC 059-11).The numbers of rats used in 
each experimental group are shown in the Table I. 































LPS injected rats- Immunofluorescence 
 


















2.1.1 Injection of LPS 
Wistar rats aged 5- and 28-days received an intraperitoneal (i.p.) injection of 
100μl of lipopolysaccharide (LPS) (1mg/kg; Cat. No. L2654, Sigma-Aldrich, 




MO, USA) (experimental group) or saline (control group). The rats were 
sacrificed 6h post injection and used for experiments. 
2.2 Perfusion 
Prior to perfusion, rats of 3-day, 5-day, 7-day, 14-day and 28-daywere 
anesthetized by injecting sodium pentobarbital solution (60mg/kg) 
intraperitoneally (i.p.). 
2.2.1 Materials 
 0.1M Phosphate Buffer: 
Solution B  
(178g Na2HPO4.2H2O in 10L of deionized water) 
Solution A 
(69g Na2HPO4.2H2O in 5L of deionized water)                    
1 volume of Solution A was mixed with 3 volume of Solution B and pH 
was adjusted to 7.4 
 2% Paraformaldehyde: 
2g of Paraformaldehyde in 100ml of 0.1M phosphate buffer  
 15% Sucrose: 
15g of Sucrose in 100ml of 0.1M phosphate buffer 
2.2.2 Procedure 
Two reservoirs was filled with Ringer’s solution and 2% Paraformaldehyde 
respectively. The two reservoirs are connected to a polythene tube interlinked 




with an air trap and a 19G needle (Terum Co., Japan) at the end of tube. The air 
bubbles in the tubes were removed carefully. The heart of rat was exposed by 
reflecting the thoracic cage and the pericardium using a scissor. Then, the cannula 
with Ringer‘s solution was inserted to the left ventricle and instantaneously a 
portion of right atrium was slit in order to let blood flow out. Ringer’s solution 
was allowed to flow until the lungs and liver were cleared of blood. Subsequently, 
the rat was perfused with 300ml of 2% Paraformaldehyde. Following perfusion, 
the brain was dissected out and post-fixed with 2% Paraformaldehyde for 3h and 
then stored in 15% sucrose overnight at 4°C. 
2.2.3 Preparation of frozen sections 
The brain tissue was trimmed, then embedded on a metal chuck using Lipshaw 
M-1 embedding matrix (Pittsburgh, USA) and frozen rapidly in liquid nitrogen. 
Coronal sections (30μm thick) of forebrain were cut using a cryostat (Model 
3050, Leica instruments, Germany). Subsequently, the sections were mounted on 
gelatin coated slides, and are allowed to dry for 1h at RT then stored at -20°C until 
use. 
2.3 Cell culture 
2.3.1 Primary microglial culture 
Microglia were isolated from 3-5 day old rat pups for primary culture. 
2.3.1.1 Materials 
 Fetal bovine serum FBS (Cat. No. SH30070.03, HyClone, UT) 




 Non-essential amino acid (Cat. No. M7145, Sigma, USA) 
 Antimycotic antibiotic solution (Cat.No.A5955, Sigma, USA) 
 Dulbecco’s modified eagle medium (Cat. No.SH30022.01, HyClone, UT) 
 Insulin (Cat. No. I0516, Sigma, USA) 
 DeoxyribonucleaseⅠ (Cat. No. D4527, Sigma, USA) 
 Trypsin-EDTA 10X (Cat. No. 15400-054, Life Technologies, USA) 
 70µm nylon mesh cell strainer (Cat. No. 352350, BD Biosciences, USA) 
 Lectin (Cat. No. L0401 ,Sigma, USA,) 




Rat pups were anesthetized with an i.p. injection of sodium pentobarbital (50 
mg/kg). The skin covering the head was cleaned with 70% ethanol and incised 
and the skull was cut opened. The cortex of brain was transferred to asterile 
petridish containing ice-cold PBS and cleaned of the meninges. The brain tissue 
was transferred into 50ml centrifuge tube and dispersed using DMEM containing 
1ml of Trypsin-EDTA with 0.5% of Trypsin and 0.2% of EDTA and then 100μl 
of DeoxyribonucleaseⅠsolution (50µg/ml). Subsequently, the cell suspension 
was transferred to a 75cm2 tissue culture flask and shaken in an orbital shaker 
(200rpm/min) for 15min at 37°C. The cells were then filtered using the 70μm 
nylon mesh cell strainer to remove the tissue clumps. At last, the cell suspension 





culture flask containing DMEM supplemented with 10% FBS and 




cultured at 37°C incubator in a humidified chamber with 5% CO2 / 95% air. The 
medium will be replaced with fresh complete media for every 48h until we 
observe 80-90% confluency of growth, which takes nearly 2 weeks. The 
heterogenous glial culture were purified by mild trypsinization (Saura et al., 
2003).Initially, the glial culture was washed twice with 1X PBS. Then it is 
incubated for 10min in trypsin solution composed of 1ml of 0.25% trypsin  and 
20μl of 0.5M EDTA diluted in 40ml of DMEM. The upper cell layer (containing 
other glial cells) detached was discarded, while the adherent microglial cells were 
again cultured in DMEM containing 10% FBS overnight. For immunostaining, 
2.5X 10
5
 cells were seeded per well on the poly-L-lysine coated coverslips of a 24-
well plate. The purity of microglia were determined by immunofluorescence 
using Lectin (1:100), which is a marker for microglia. 
2.3.2 BV-2 microglial cell culture 
BV-2 cells are immortalized murine microglial cell line, was used in the present 
study (Henn et al., 2009; Stansley et al., 2012).  
2.3.2.1 Materials 
 Fetal bovine serum FBS (Cat. No. SH30070.03, HyClone, UT) 
 Dulbecco’s modified eagle medium (Cat. No.SH30022.01, HyClone, UT) 
 Trypsin-EDTA (Cat. No. T4174, Sigma, USA) 
 Phosphate Buffered Saline, 10XPBS (Cat. No. PB0344-1L, Vivantis, 
USA) 
 75cm2 tissue culture flasks (Corning, USA) 





BV-2 cells were grown in 75cm
2
 cell culture flask containing DMEM 
supplemented with 10% FBS in a humidified chamber filled with 5% CO2 and 
95% air at 37°C for 3-4 day. The cells were passaged every two days and  replated 
in fresh medium. Briefly, the cells were washed with twice of 1X PBS and then 
treated with 5ml of 1X TE in PBS at 37°C for 5min. The effect of TE was 
neutralized by addition of 10ml of DMEM containing 10% FBS. The cell 
suspension was taken in a 50ml centrifuge tube and centrifuged at 1000rpm at 4°C 
for 5min.  The pellet was suspended with 10ml of complete medium and the 
supernatant was discarded off. Then the cells were seeded in either 24 well plates 
for immunostaining or in 6 well plates for isolation of RNA isolation. 
2.3.3 Treatment of BV-2 cells 
2.3.3.1 Material 
 Lipopolysaccharide LPS (Cat. No.  L2654, Sigma, USA)  
2.3.3.2 Procedure 
BV-2 cells were cultured in culture dishes in DMEM supplemented with 10% 
FBS. After 12h, the cells were washed twice with 1X PBS, and then treated with 
LPS (1μg/ml in DMEM).  Following addition of LPS, the cells were incubated for 
different time points (1h, 3h, 6h) before they were used for various experiments. 
The basis for selection of time points is for two reasons: first to see whether LPS 
had time dependent function on inflammation and secondly what is the time at 




which Dpysl3 is maximally expressed. This would give an estimate of direct 
relationship between Dpysl3 and magnitude of inflammation. 
2.4 siRNA mediated gene knockdown 
2.4.1 Principle 
RNA interference technology has shown that level of target gene 
expression can be effectively silenced by the introduction of short double-
stranded RNA oligonucleotides to mammalian cells. The siRNAs are cleaved 
from double stranded RNAs by DICER (RNase III –like enzyme) (Tauser and 
Stoica, 2003). This short siRNA pieces (20-25bp) unwind to single stranded RNA 
and bind with proteins, forming a multi-subunit protein complex termed as RNA-
Induced Silencing Complex (RISC). This  protein complex guides the siRNAs to  
its target mRNA sequence, leading to degradation of complementary mRNA 
sequence with help of endo and exonucleases (Tauser and Stoica, 2003). When 
the pairing is perfect between native mRNA and siRNA sequence, the native 
mRNA becomes fragmented, and hence it cannot be translated (Gavrilov and 
Saltzman, 2012).  
2.4.2 Materials 
 Predesigned siRNA (Ambion, USA) 
 OPTIMEM I reduced serum medium (Cat. No. 31985-070, Life 
technologies, USA) 
 Negative Control siRNA, silencer select, 5nM (Cat. No. 4390843, 
Ambion, USA).  




 Lipofectamine RNA iMAX transfection reagent (Cat. No. 13778150, Life 
technologies, USA) 
 
The siRNA sequences for Dpysl3 are shown in Table II: 
 




BV-2 cells were plated at a density of 2x10
5
 cells/ml and grown in DMEM 
containing 10%FBS (2ml) for 24h to achieve maximum confluency. 500μl 
Opti-MEM with 10μl of predesigned siRNA (50nm) and 4μl of Lipofectamine 
with 500μl Opti-MEM were incubated for 10min at 37°C in separate tubes. 
Following incubation, the two solutions were combined and incubated at 37°C 
for 20min to form siRNA-Lipofectamine complex. After 20min, the BV-2 
cells were incubated in Opti-MEM containing siRNA-Lipofectamine complex 
for 8.5h. After 8h of incubation, the Opti-MEM medium was changed with 
DMEM containing 10% FBS. For the control, the BV-2 cells transfected with 









Anti-sense: 5’- UGGUGGUCAAGUCAAACACtg-3’ 




scrambled (negative control) siRNA were used. The transfected cells were 
cultured for 48h, after which the knockdown efficiency was determined by 
qRT-PCR.  
2.5 RNA isolation and quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) 
2.5.1 Principle 
The RNA isolation was performed using the RNeasy kit (Qiagen, Germany), 
which uses micro spin technology. The cell samples are lysed with  guanidium 
isothiocyanate (GITC) buffer by which the RNases are inactivated to extract the 
RNA. The ethanol is added in order to provide binding conditions for the RNA 
samples and then added to spin column. In the spin column, RNA longer than 200 
bases is adsorbed on a silica-gel membrane based on its selective binding 
properties and remaining contaminants are discarded. High grade quality RNA is 
eluted in RNase-free water. Using this  protocol, longer RNA molecules of about 
200 nucleotides are extracted and shorter RNA nucleotides namely 5S rRNA, 
tRNAs and 5.8S rRNA, are excluded (Qiagen RNeasy Mini handbook). 
Polymerase chain reaction (PCR) is a method that amplifies several copies 
of specific region of DNA. A PCR reaction consists of 3 major steps: 
denaturation, annealing and DNA synthesis (repeated for 30-40 cycles). In this 
process, the double strand DNA (template) is denatured to become a single 
stranded DNA which then hybridized to a set of 5’ and 3’ primers (20 nucleotides 
in length and are complementary to a defined sequence of the gene of interest). 




Then, DNA polymerase and polynucleotides extend the primers and make a copy 
of designated DNA sequence. Due to complementary nature of primers with both 
strands of DNA, the reaction continues to produce more copies of DNA 
(Belokhvostov, 1995).  
The combination of reverse transcription and polymerase chain reaction 
(RT-PCR) is a powerful method to quantify the levels of mRNA expression. The 
quantitative RT-PCR using fluorescent probes is extremely sensitive for the 
quantification of gene expression. This method uses a SYBR green which is a 
fluorescent dye that binds to the double stranded DNA.  During the extension 
step, increasing amounts of dye bind to newly synthesized hence the double 
stranded DNA increases its fluorescence signal intensity (Arya et al., 2005). 
Hence, the measured fluorescent intensity indicates the amount of amplified 
DNA.  Therefore the assessment of  2
-ΔΔCt  
indicate the fold change of target gene 
expression normalized to endogenous reference gene (Livak and Schmittgen, 
2001).  
2.5.2 Materials 
 RNeasy Mini Kit (Cat. No. 74106, Qiagen, Germany) 
 RNase inhibitor RNasin (Cat. No. N2511, Promega, USA) 
 Moloney murine leukemia virus reversetanscriptase-5Xbuffer (Cat. No. 
M531, Promega, USA) 
 Moloney murine leukemia virus reverse transcriptase (Cat. No. M1701, 
Promega, USA) 
 Olido(dT) 15 Primer (Cat. No. C1101, Promega, USA) 




 10mM dNTP  (Cat. No. U1511, Promega, USA) 
 RNase-free water 
 Fast SYBR Green Master Mix (Cat.No.4385612, Applied Biosystems, 
USA) 
 TAE buffer (Cat. No.PB09040-1L,Vivantis,USA)  
 100bp DNA ladder (Cat. No. G6951, Promega, USA)  
 RT-PCR instrument (Applied Biosystems 7500HT) 
 Gene Genius (Syngene, UK)  
 Spectrophotometer (Eppendorf, Germany) 
2.5.3 RNA extraction 
Total RNA was extracted from control and LPS treated BV-2 cells using the 
RNeasy mini kit. First, the cells were lysed in 650μl of RLT lysis buffer for 10-
15min on ice and then scraped. The cell  lysate was homogenized and centrifuged 
at 14000×g for 30s. To the supernatant, 650μl of ethanol was added to clear the 
cell lysate. The samples were transferred to RNeasy mini spin column and 
centrifuged at 14000×g for 30s and the flow through was discarded. Then the spin 
column was washed with RW1 and RPE buffers. Finally, the RNA is eluted by 
adding   20μl of RNase free water to the spin column. The quality of the extracted 
RNA was assessed at 260 and 280nm using the Nanodrop (Biophotometer, 
Eppendorf, Germany). The RNA samples were then stored at -80°C for further 
use. 




2.5.4 cDNA Synthesis 
2.5.4.1 Materials 
 RNase inhibitor RNasin (Cat.No.N2511, Promega, USA) 
 Moloney murine leukemia virus reverse tanscriptase- 5X buffer (Cat. No. 
M531, Promega, USA) 
 Moloney murine leukemia virus reverse transcriptase (Cat. No. M1701, 
Promega, USA) 
 Olido(dT) 15 Primer(Cat. No. C1101, Promega, USA) 
 10mM dNTP (Cat.No.U1511, Promega, USA) 
 RNase-free water 
2.5.4.2 Procedure 
Moloney murine leukemia virus (M-MLV) Reverse Transcriptase is an  RNA 
dependent DNA polymerase  enzyme used for synthesis of cDNA from the RNA. 
1μl of Oligo (dT)15 primer  was added to 2μg of RNA sample in a 
microcentrifuge tube and heated to 70°C for 5min, following which the tubes 
were incubated on ice. The reaction mixture containing 1µl of M-MLV RT, 5µl of 
M-MLV RT 5x buffer，0.675µl of RNasin inhibitor, 1.2µl of dNTP mix and 
RNase free water (which makes upto a final volume of 25μl) was added to the 
tube and incubated at 42°C for 1h. Then, the reaction was stopped by heating for 
15min at 70°C and the synthesized cDNA was then stored at -20°C until use. 




2.5.5 Quantitative real-time -PCR 
Quantitative real time-PCR was carried out on an Applied Biosystems 7900HT. 
The primer sequences used are tabulated in Table III: 
Table III: Primer sequences for RT-PCR 
 
Each reaction mixture contains 0.5µl of 5mM gene specific primers, 5µl of PCR 
master mix, 1µl of cDNA and RNase free water (to a final volume of 10µl). The 
real time PCR was performed in triplicates using the following program 95°C for 
15min, followed by 40 cycles of denaturing at 94°C for 15s, annealing at 60°C for 
















Reverse primer-5'- CTCACTGGGACAGCACAGAA-3' 
217bp 
Dpysl3 












Forward primer- 5’- GGATTCCATACCCAAGAAGGA-3’ 
Reverse primer- 5’- GAAGAGCTATGAGCTGCCTGA-3’ 
103bp 




with the -actin product and analyzed using the 2
-ΔΔCt  
(Livak and Schmittgen, 
2001) method. 
2.5.6 Detection of PCR products 
2.5.6.1 Materials 
 1% agarose gel:  
Agarose (Vivantis, USA)           1g 
Ethidium Bromide solution (Bio-Rad)                1μl 
1X TAE buffer (Vivantis, USA)                 100ml 
 100bp cDNA Ladder (Cat.No.G2101, Promega, USA) 
2.5.6.2 Procedure 
The PCR products were analyzed on 1% agarose gel using the gel electrophoresis 
equipment. 1% agarose gel was prepared in 1X TAE buffer and then 1μl of EtBr 
was mixed with the heated agarose solution and then was poured and solidified in 
the gel tray. 10μl of PCR product mixed with 2μl of 6x loading dye was added to 
each lane of the agarose gel and gel was ran on an electrophoresis tank containing 
1X TAE buffer at 110V for 30min. The PCR products were visualized and 
photographed using a gel documentation system. 
2.6 Western blotting 
2.6.1 Principle 
Western blotting is an analytical technique that determines the amount of proteins 
in samples. In this technique, a complex protein mixture is separated by 




electrophoresis based on its molecular size, then transferred to a PVDF or 
nitrocellulose membranes and detected with specific primary antibodies. Primary 
antibodies detect only specific protein antigen on the membrane. Antigen-
Antibody complexes are detected using secondary antibodies conjugated with 
horseradish peroxidase (HRP) (Kurien and Scofield, 2006). The 
chemiluminescence HRP substrate was used to develop the protein expression on 
X-ray film. 
2.6.2 Materials 
 Rabbitanti-Dpysl3 (Cat. No. AB5454, Millipore, USA) 
 Goat anti-Dpysl3 (Cat. No. SC-27323, Santa Cruz, USA) 
 Rabbit anti-TNF-α (Cat. No. AB2148P, Chemicon, USA) 
 Rabbit anti-IL-1β (Cat. No.AB1413, Chemicon, USA,) 
 Rabbit anti-iNOS(Cat. No. SC-649, Santa Cruz, USA) 
 Rabbit anti-NF-κB(Cat. No. SC-372, Santa Cruz, USA) 
 Mouse anti-Rac1 (Cat. No. SC05-389, Millipore, USA) 
 Mouse anti-RhoA (Cat. No. SC418, Santa Cruz, USA) 
 Mouse anti- βactin (Cat. No.55441 , Sigma, USA)  
 Goat-anti-Mouse horseradish peroxidase (Cat. No. 31430, Thermo 
scientific, USA) 
 Goat anti-Rabbit horseradish peroxidase (Cat. No. 31460, Thermo 
scientific, USA) 




 Mammalian protein extraction reagent (Cat. No. 88665, Thermo 
scientific, USA) 
 Protein assay kit (Cat. No. 5000002, Bio-Rad, USA) 
 Pierce Protease inhibitor (Cat. No. 88665, Thermo scientific, 
USA)Western blot stripping buffer (Cat. No. 46430, Thermo scientific, 
USA) 
 6x SDS gel-loading buffer 
 10% Resolving gel: 
H2O           7.9ml 
30% Acrylamide mix         6.7ml 
1.5M Tris (pH8.8)         5.0ml 
10%SDS          0.2ml 
10% Ammonium persulfate        0.2ml 
TEMED                0.008ml 
 5% Stacking gel: 
H2O           5.5ml 
30% Acrylamide mix         1.3ml 
1.5M Tris (pH6.8)         1.0ml 
10% SDS         0.08ml 
10% Ammonium persulfate      0.08ml 
TEMED               0.0008ml 
 Running buffer: 10X Tris-Glycine-SDS (Cat. No. 161-0732, Bio-Rad, 
USA)  




 Transfer buffer: 10X Tris-Glycine (Cat. No. 161-0734, Bio-Rad, USA) 
 1X TBS: 
Tris base                       2.42g 
NaCl                       0.8g 
Made upto 1L with deionized water of pH 7.4. 
 1X TBST 
1X TBS                           1L 
0.1%Tween 20 
2.6.3 Procedure 
BV-2 cells (control and experimental groups) cultured in 6 well plates were 
washed twice with ice cold PBS.  600μl of protein extraction buffer was added per 
well and incubated for 10min on ice. The cells were then scraped using cell 
scraper and the cell lysate was centrifuged at 14,000×g at 4°C for 15min. The 
supernatant containing total protein was collected and stored at -20ºC for further 
use. A standard curve was plotted using Protein Assay Standard Lyophilized 
Bovine Serum (1.25mg/ml) protein assay kit. The standard proteins were prepared 
using BSA with the following concentrations 0.06, 0.12, 0.24, and 0.48mg/ml in a 
96-well plate. 200μl of dye reagent was mixed with 10μl of each standard or 
sample and was added to each well in a 96-well plate. The sample/standard 
mixtures were incubated for 15min at RT, and its absorbance was examined at 
595nm using microplate reader (GENios, Tecan, Switzerland). Then the 
concentration of samples was calculated based on the standard curve. 20μg of 
each protein extract was mixed with 1x SDS gel-loading buffer and heated to 




95°C for 5min to denture the proteins. The denatured proteins were subjected to 
SDS-PAGE and were separated based on its molecular size. Using the semi-dry 
electrophoretic transfer equipment (Bio-Rad, USA), the separated proteins were 
transferred to PVDF membrane. The membrane blots were blocked with 5% non-
fat milk protein in 1X TBST at RT for 1h and then incubated with primary 
antibodies at 4ºC overnight. The following primary antibodies were used: rabbit 
anti-Dpysl3 (1:500) /Goat anti-Dpysl3 (1:250), rabbit anti-TNF-α (1:500), rabbit 
anti- IL-1β (1:500), rabbit anti- NF-κB (1:250) and mouse anti-actin (1:10000). 
Following day, the blots were washed thrice with 1X TBST for 15min and 
incubated with secondary antibody conjugated horseradish peroxidase (HRP) for 
1h at RT. The immunoblots were washed thrice with 1X TBST and then 
developed using chemiluminescence (ECL). The membrane blots were stripped 
with stripping buffer and reprobed with β-actin as control. The optical density for 
each protein bands were quantified using the Quantity One software (Bio-Rad, 
USA). 
2.6.4 Cytoplasmic and nuclear protein extraction 
The cytoplasmic and nuclear components of the cells were extracted using the 
nuclear and cytoplasmic extraction kit (Pierce, Thermo Scientific, Catalog 
no.78833). The BV-2 cells transfected with scrambled siRNA and Dpysl3 siRNA 
were trypsinized and the cell pellets were washed with thrice with 1X PBS. To the 
cell pellet, 100μl of (CER-I) cytoplasmic extraction reagent –I was added and 
vortexed for 15s. The mixture was then incubated in ice for 10min. Following 
this, 5.5μl of cytoplasmic extraction reagent –II (CER-II) was added to the 




mixture and then was incubated for 1min in ice. The mixture was then centrifuged 
at 16,000 g for 5min and the supernatant containing the cytoplasmic extract was 
transferred to a separate tube. To the cell pellet 50μl of nuclear extraction reagent 
was added and then was incubated in ice for 40min and was with vortex for 
10min each. The mixture was then centrifuged for 10min at 16,000g and the 
supernatant containing the nuclear extract was stored at -80°C for further use. 
2.7 Immunohistochemistry and Immunofluorescence staining 
2.7.1 Principle 
Immunohistochemistry (IHC) is highly sensitive technique that helps to visualize 
the distribution and localization of specific antigens and cellular components 
within tissues (Hachmeister and Kracht, 1975). In this technique, antigens can be 
detected using fluorescent probe or chromogen. In immunofluorescence 
technique, the antibodies are conjugated with a fluorescent dye and the antigen-
antibody complex is visualized through a fluorescence microscope (von dem 
Borne et al., 1978). First, the cell/tissue samples are fixed to retain the cellular and 
subcellular architecture. This is followed by a blocking step that prevents non-
specific binding of primary antibodies. The Immunofluorescence staining 
comprises of direct and indirect method. In direct staining method, the primary 
antibody is labeled with fluorescent dye and in indirect method, the secondary 
antibody is labeled with a flurochrome which recognizes the primary antibody 
(Beutner, 1961). 




2.7.2 Immunofluorescence labeling 
2.7.2.1 Materials 
 Rabbit anti-Dpysl3 (Cat. No. AB5454, Millipore, USA) 
 Goatanti-Dpysl3 ((Cat. No.SC-27323, Santa Cruz, USA) 
 Mouse anti-OX-42 (Cat. No. CBL 1512, Chemicon, USA) 
 Rabbit anti-TNF-α (Cat. No. AB2148P, Chemicon, USA) 
 Rabbit anti-IL-1β (Cat. No.AB1413, Chemicon, USA,) 
 Rabbit anti-iNOS (Cat. No. SC-649, Santa Cruz, USA) 
 Rabbit anti-NF-κB (Cat. No. SC-372, Santa Cruz, USA)  
 Mouse anti-Rac1 (Cat. No. SC05-389, Millipore, USA) 
 Mouse anti-RhoA (Cat. No. SC418, Santa Cruz, USA) 
 DAPI (Cat. No. D1306, Molecular Probes, USA) 
 Lectin (Cat. No. L0401, Sigma, USA) 
 Anti-Rabbit Cy3 (Cat. No. C2306, Sigma, USA) 
 Anti-Mouse FITC (Cat. No. F9137, Sigma, USA) 
 Anti-Rabbit FITC (Cat. No. F6005, Sigma, USA) 
 0.1M phosphate buffer, pH-7.4 
 10X Phosphate buffer saline PBS (Cat. No. PB0344-1L, Vivantis, USA) 
 4% Paraformaldehyde: 
Paraformaldehyde-                   4g 
0.1M phosphate buffer -       100ml 
2.7.2.2 Brain tissue sections 




The tissue sections were rinsed in PBS (thrice for 10min each), and blocked with 
5% normal goat serum or normal horse serum for 1h. The sections were incubated 
with rabbit anti-Dpysl3 (1:500)/Goat anti-Dpysl3 (1:200) and mouse OX-42 
(1:50) antibody at 4°C overnight. The following day, the tissue slides were 
washed thrice with 1X PBS and then incubated with Cy3 or FITC conjugated 
secondary antibodies for 1h in the dark. Finally, the sections were counterstained 
with DAPI and mounted using the DAKO fluorescent mounting medium.  The 
tissue sections were visualized using a Confocal microscope (Fluoview, FV1000; 
Olympus, Tokyo, Japan). 
2.7.2.3 BV-2 cells-Poly-lysine coating of coverslips 
The sterilized cover slips were plated in each well of 24-well plate. 400µl of poly-
L-lysine was added to each coverslips and the plate was incubated for 3h at RT. 
After the incubation time, the wells were washed thrice with 1X PBS and then 
theBV-2 cells were seeded. 
BV-2 cells (control and experimental groups) were washed thrice with 1X 
PBS and fixed in 4% PF for 30min at RT. Then the cells were washed and then 
blocked with 5% normal goat serum for 1h. Following incubation, the cells were 
incubated with primary antibodies directed against rabbit anti-Dpysl3 
(1:500)/Goat anti-Dpysl3 (1:200),or rabbit anti- TNF-α (1:200), or rabbit anti- IL-
1β (1:200), or rabbit anti- iNOS (1:200), or rabbit anti-NF-κB (1:200), or mouse 
anti-RhoA (1:200) and mouse anti-Rac1 (1:200) at 4°C overnight. The following 
day, the cells were washed thrice with 1X PBS 10min and then incubated with 




Cy3/FITC-conjugated secondary antibodies for 1h at RT. Then the cells were 
stained with Lectin for 30min and counterstained with DAPI for 3min. Finally, 
the cells were washed with 1X PBS and coverslips were mounted with DAKO 
fluorescent mounting medium. The slides were visualized using a Confocal 
microscope.  
2.7.2.4 F-actin labeling 
2.7.2.4.1 Material 
 Phalloidin-Rhodamine (Cat. No. PHDR1, Cytoskeleton Inc., USA) 
2.7.2.4.2 Procedure 
The actin cytoskeleton in microglia was detected using Phalloidin-Rhodamine 
(3.5µl:500µl of PBS) dye. BV-2 microglial cells grown on coverslips were ﬁxed 
with 4% PF for 30min at RT. The BV-2 cells were washed thrice in 1X PBS and 
then incubated with Phalloidin-Rhodamine (according to the manufacturer’s 
instructions) for 30min at RT. Following incubation, the cells were washed thrice 
with 1X PBS and the coverslips were mounted using DAKO fluorescent 
mounting medium onto the slides (Christensen et al., 2006). 
2.8 in vitro migration assay 
2.8.1 Materials 
 Polycarbonate membrane transwell inserts, 8µm pore size (Cat. No. 3422, 
Corning, USA) 




 Lipopolysaccharide LPS (Cat. No.  L2654, Sigma, USA)  
2.8.2 Procedure 
The migration of microglia in vitro was evaluated using 8µm pore size 
polycarbonate membrane transwell inserts. The BV-2 cells transfected with 
scrambled siRNA (negative control) and Dpysl3 siRNA were grown in 6-well 
plates. To examine chemotactic migration, the transfected BV-2 cells were 
trypsinized and added at a density of 5× 10
4 cells in 200μl of serum-free medium 
to the upper well of the transwell insert. 500μl of serum free medium with and 
without LPS was applied to the bottom of transwell insert (Kim et al., 2006a; 
Karlstetter et al., 2011). The BV-2 cells in transwell insert were incubated for 24h 
in a humidified incubator filled with 5% CO2 and 95% air at 37°C. The cells 
present on the upper layer of the transwell insert were removed with a moist 
cotton swab, and the transfected cells migrated to the bottom layer of the insert 
were fixed with methanol for 15min at RT and then stained using 1% crystal 
violet. The migrated cells on the bottom layer of the transwell insert were 
quantified and captured using the light microscope (Leica, CLS150X, Germany). 
2.9 Phagocytosis 
2.9.1 Materials 
 0.8μm latex beads (Cat. No. L398, Sigma, USA) 





Phagocytosis was assayed using latex beads (Marker et al., 2012). At first, the 
BV-2 cells transfected with scrambled siRNA and Dpysl3 siRNA for 48h in a 24-
well plate. Following transfection, the transfected BV-2 cells were stimulated 
with LPS (1μg/mL) in DMEM for 1h. To examine the microglial phagocytic 
activity, 1μl/ml of 0.8μm latex beads (Sigma) were added to each well and then 
incubated for 2h at 37°C in a humidified chamber filled with 5% CO2 and 95% 
air. Following transfection, the transfected BV-2 cells were fixed with 4% PF for 
20min and excess beads were removed by washing thrice with ice cold 1X PBS 
for 10min each. Phagocytic cells were visualized and captured under confocal 
microscope with phase contrast settings. Phagocytic cells (containing minimum of 
10 beads per cell) were counted in each microscopic field (Allen et al., 2002). 
2.10 Nitric oxide assay 
2.10.1 Principle 
Nitric oxide (NO) plays a vital role in immune response, neurotransmission and 
apoptosis. Nitric oxide is oxidized to nitrite and nitrate to determine NO 
production. Nitric oxide colorimetric bioassay kit measures NO in a two step 
process. The first step involves conversion of nitrate to nitrite using the nitrate 
reductase enzyme. The second step uses Griess reagents that converts nitrite to a 
purple azo compound (US Biological Nitric Oxide Colorimetric BioAssay Kit 
handbook).The amount of azo chromophore determines the amount of nitric oxide 
in samples (Stone et al., 2006). 





 Nitric Oxide Colorimetric BioAssay Kit (Cat. No. 2577-01, US 
Biological,Massachusetts, USA) 
2.10.3 Procedure 
The quantity of NO was measured using the colorimetric nitric oxide assay kit 
with a Griess reagent system. Culture supernatant from the BV-2 cells transfected 
with scrambled siRNA and Dpysl3 siRNA was collected 1h after LPS treatment. 
At first, 200μl/well of diluted assay buffer was coated to a  96 well plate, and then 
80μl/ well of the supernatants were added to it. Later, 10μl/well of the enzyme 
cofactor mixture and then 10μl/well of the reconstituted nitrate reductase were 
added to the wells subsequently. The plates were covered and incubated for 1-4h 
at RT, then 50μl/well of Griess reagent R1 and 50μl of Griess reagent R2 were 
added immediately. A colored product developed within 10min at RT and the 
absorbance was measured at 540nm with EMAX precise microplate reader 
(Molecular Devices, USA).  The NO production of the samples was calculated 
using standard curve obtained from the nitrate standard using the formula: 
[Nitrate+Nitrite](μM)=[(A540-
Yintercept)/(slope)x(200μl/samplevolume(μl))]xDilution. 




2.11 Cell viability assay 
2.11.1 Material 
 CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Cat. No. 
G3582, Promega, USA) 
2.11.2 Procedure 
The viability of siRNA transfected BV-2microgliawere measured using CellTiter 
96 Aqueous One Solution Cell Proliferation Assay kit. The transfected BV-2 cells 
were seeded at a density 2.0×10
5
 in a 6-well plate and then transfected with 
scrambled siRNA (negative control) andDpysl3siRNA. 200μl/well of MTS 
reagent was added toeach seeded well and the plate was incubated for 4h in a 
humidified chamber of 5% CO2 and 95% air at 37°C. Following the incubation, 
the absorbance was measured at 490nm using a microplate reader (GENIOS, 
Tecan, Switzerland). The absorbance measured is proportional to the number of 
BV-2 cells seeded in each well at different conditions.  
2.12 BrdU assay 
2.12.1Principle 
Bromodeoxyuridine (BrdU) is a thymidine analog that incorporates into the newly 
synthesized DNA strands of actively proliferating cells (Rothaeusler and 
Baumgarth, 2007; Lehner et al., 2011). Anti-BrdU antibodies are used to detect 
the incorporated BrdU in cellular DNA. The number of BrdU positive cells can be 
quantified to determine the rate of cell proliferation. 





 Mouse anti-BrdU monoclonal antibody (Cat. No. B2531, Sigma, USA) 
 Anti-Mouse Cy3 (Cat. No. C2181, Sigma, USA) 
 Lectin (Cat. No. L0401, Sigma, USA) 
 Fluorescent Mounting Medium (Cat. No. S302380, Dako Cytomation, 
Denmark) 
 Phosphate Buffered Saline, 10XPBS (Cat. No.PB0344-1L, Vivantis, USA) 
 1X PBS containing 0.1% Triton-X 100 (PBS-TX) 
 4% Paraformaldehyde (PF) 
Paraformaldehyde-4g 
0.1M Phosphate buffer pH-7.4-100ml 
2.12.3 Procedure 
The transfected BV-2 cells were incubated with BrdU (10µmol/l) for 2h, then the 
cells were washed with twice of 1X PBS-TX and then fixed with 4% PF for 
20min at 4ºC. Next, the fixed cells were treated with 2NHCl at 37ºC for 30min 
and then washed thrice with 1X PBS-TX.  Subsequently, the cells were blocked 
with 5% normal goat serum for 1h, and incubated with anti-BrdU monoclonal 
antibody (1:1000) overnight at 4ºC. Further, the cells were washed with twice of 
1X PBS and incubated with goat anti-mouse secondary antibody conjugated with 
Cy3 (1:200) for 1h at RT. Then the cells were counterstained with Lectin (1:300) 
for 30min and DAPI. Finally, the coverslips were mounted with DAKO mounting 
medium and visualized in a Confocal microscope. The percentage of BrdU 








Co-immunoprecipitation is a widely used technique to identify protein-protein 
interactions. Co-immunoprecipitation is based on immunoprecpitation which 
shares the principle of antigen-antibody interaction (Masters, 2004). In this 
method, an antibody specific for a target protein forms an immune complex and 
binds to its target in a cell lysate. This immune complex is precipitated using 
agarose A/G beads. The agarose beads are immobilized with the antibody binding 
protein and other proteins that are not precipitated are washed away. Following 
this step, the purified sample is subject to SDS-PAGE and western blot to identify 
the antigen.  
2.13.2 Materials 
 Agarose G beads (Cat. No. 20398, Pierce, USA) 
 Control Mouse Isotope IgG (Cat. No. SC2025, Santa Cruz, USA) 
 Mouse anti-Rac1 (Cat. No. SC05389, Millipore, USA) 
 Mouse anti-RhoA (Cat. No. SC418, Santa Cruz, USA) 
 Mouse anti-Dpysl3 (Cat. No. 100323, Santa Cruz, USA) 
 RIPA lysis Buffer: 
5M NaCl                 500μl  




1M Tris pH8.0                2500μl  
0.5M EDTA                 100 μl  
Triton-100                 50 μl  
Sodium Deoxycholate               0.05g 
10% SDS                 250μl  
1XProteinase inhibitor                         5000 μl 
 Deionized water make up the volume to 50ml.  
 
2.13.3 Procedure 
BV-2 cells are washed twice with ice cold 1X PBS and then incubated with 1ml 
of  RIPA lysis buffer for 10min on ice. The cells were scraped using a cell scraper 
transferred to a centrifuge tube. The tubes were incubated for 30min in an end-to-
end shaker at 4°C. The cells were centrifuged for 13,200 rpm for 10min at 4°C. 
The protein supernatant was collected and quantified using protein assay kit. The 
protein sample is mixed withDpysl3 antibody (4µg) and incubated in the shaker 
overnight at 4°C. For the control, the protein samples were mixed with isotype 
control mouse IgG antibody and incubated in the shaker at 4°C overnight.  The 
next day, 20μl of agarose G beads are added to the control isotypic and antibody 
mixed samples and incubated for 1h in the shaker at 4°C. Later, the protein 
samples are centrifuged at 300rpm for 1min at 4°C, the supernatant was discarded 
off. The beads were washed thrice with RIPA buffer and centrifuged at 300rpm at 
4°C for 1min, and then the protein supernatant was removed without losing the 
beads. The bead samples are mixed with 20μl of 2x SDS and boiled to 95°C for 5 




min, then the samples were spun and the supernatant were  collected  and loaded 
on SDS-PAGE. 
2.14 Quantitative analysis 
The number of Dpysl3-positive microglial cells was counted from at least 5 tissue 
sections cut through the corpus callosum (30µm thickness) from 3 different brain 
samples. The percentage of Dpysl3-positive cells was calculated by counting the 
number of Dpysl3-positive cells in OX42-stained microglial cells and the total 
number of OX42–positive microglial cells in a specified unit area on each section. 
The average immunofluorescence intensity of Dpysl3 in BV-2 microglial cells 
was calculated using the software (Fluoview, FV1000). The Dpysl3 
immunofluorescence staining in an individual BV-2 microglial cell was captured 
using a Confocal microscope. About 15 microglial cells from 3 different slides of 
each group were selected and outlined, and then the mean value of the Dpysl3 
staining intensity of outlined BV-2 microglia was measured. The Fold change was 
calculated (Lin et al., 2011). 
2.15 Statistical analysis 
 All experiments were performed in triplicates. The difference between 
experimental and control groups was calculated  by one way analysis of variance 
(ANOVA) followed by Bonferroni test using the graph pad prism5 software.  The 
data are represented as mean ± SD from at least three independent experiments 

























3.1 Differential expression of Dpysl3 in the developing rat brain 
The amoeboid microglial cells (AMC) have been shown to be predominant in the 
corpus callosum (CC) region  (Fig.1)  of the postnatal rat brain  (Ling and Wong, 
1993).  The expression of Dpysl3 in developing rat brains (3, 5, 7 and 14 days) 
was examined by immunofluorescence technique (Fig 2B-M). Dpysl3 was found 
to be highly expressed in AMC of 3-day rats and the expression decreased 
progressively in 5-day and 7-day rats (Fig.2C, F, and I). In 14-day rat pups, the 
expression of Dpysl3 was hardly detectable in ramified microglia (RMC) 
(Fig.2L). Quantitative analysis revealed that the percentage of Dpysl3-postive 
AMC was markedly more in CC of 3-day and 5-day old rat pups when compared 
to 7-day and 14-day old rat pups (Fig.2N). 
3.2 Expression of Dpysl3 is increased in activated microglia 
3.2.1 In LPS injected rat brains 
The expression of Dpysl3 in activated microglia was examined by 
immunofluorescence in 5-day old and 28-day old rats treated with LPS. In the CC 
of 5-day old rats injected with LPS, the expression of Dpysl3 was found to be 
increased in AMC when compared to the control rats that were injected with 
saline (Fig.3A-F). Quantitative analysis revealed that the percentage of Dpysl3-
positive microglial cells was increased significantly in LPS treated 5-day old rat 
pups than that of control (Fig.3G).  Similarly, the expression of Dpysl3 was 
increased in CC of 28-day rat brains injected with LPS when compared to the 





positive microglial cells was increased in CC significantly in LPS-treated 28 day 
rats when compared to the control (Fig.4G). 
3.2.3 Activated microglial cultures 
3.2.3.1 Primary microglia  
The immunofluorescence expression of Dpysl3 was localized in primary 
microglia (Fig.5A-F). The expression level of Dpysl3 was increased in activated 
microglia by LPS (Fig. 5D-F) when compared to the control (Fig.5A-C). 
3.2.3.2 Murine microglial cell line, BV-2 
The expression of  Dpysl3 in mouse microglial cell line, BV-2 was investigated in 
various time points (1h, 3h, 6h) of LPS administration. The expression of Dpysl3 
mRNA was found to be upregulated significantly (~2.8 fold) in BV-2 microglia 
following LPS treatment for 1h and decline subsequently at 3h and 6h of LPS 
treatment (Fig.6A, B). Immunofluorescence analysis revealed that the expression 
of Dpysl3 protein was increased in BV-2 cells following LPS treatment for 1h as 
compared to control (Fig 6C-F). However, the increase of Dpysl3 expression was 
not evident in BV-2 cells treated with LPS for 3-6h.The expression level of 
Dpysl3 protein was examined in LPS activated BV-2 cells by western blot 
(Fig.6G, H). The Dpysl3 protein level was increased significantly following LPS 
treatment for 1h in comparison to control cells. This increase was found to be 
decreased in BV-2 microglia at 3h and 6h of LPS treatment. (Fig.6G, H). The 
maximal expression of Dpysl3 was evident at 1h post-LPS treatment, the 





3.3 Distribution of  Dpysl3 in activated BV-2 microglia 
The F-actin cytoskeleton of microglia was detected by Phalloidin-Rhodamine 
labeling (Christensen et al., 2006). BV-2 microglia in control medium appeared 
immotile with cell processes retracted (Fig.7B).  In contrast, activated BV-2 
microglia cells by LPS showed actin-containing microspikes (Fig.7E). Double 
staining with Phalloidin-Rhodamine revealed the co-localization of Dpysl3 and F-
actin preferentially in actin bundles (Fig.7D-F). This result suggests that Dpysl3 is 
involved in the cytoskeletal reorganization in microglial motility. 
3.4 Dpysl3 regulates the proinflammatory cytokines and neurotoxic 
mediators in activated microglia through NF-κB signaling pathway 
3.4.1 siRNA knockdown of Dpysl3 
siRNA-mediated knockdown of Dpysl3 was performed in BV-2 cells in order to 
understand the function of Dpysl3 in microglia. qRT-PCR analysis showed that 
the expression of Dpysl3 mRNA was decreased to about 80% in Dpysl3 siRNA 
transfected cells in comparison to the cells transfected with scrambled siRNA 
(Negative Control) (Fig.8A). In order to determine if the changes in Dpysl3 
mRNA expression following transfection were due to cell death, the cell viability 
assay was carried out at 48h post transfection. About 90% of the of BV-2 
microglia were found to be viable following transfection in comparison to that of 
non-transfected BV-2 microglia (Fig.8B). The efficient siRNA-mediated 
knockdown of Dpysl3 was further confirmed by western blot analysis (Fig 8C, 





level in BV-2 microglia transfected with scrambled siRNA (negative control) 
whereas, the knockdown of Dpysl3 in BV-2 microglia treated with or without 
LPS significantly inhibited the Dpysl3 expression (Fig.8C, D). 
3.4.2 Knockdown of Dpysl3 decreases the production of  TNF-α cytokine by 
activated microglia 
Activated microglia release a number of proinflammatory cytokines namely 
TNFα, IL-1β and nitric oxide (NO) resulting in cytotoxicity to the neighboring 
neuronal cells (Smith et al., 2012). To address this, we studied the cytokines level 
in activated microglial cells following knockdown of Dpysl3 using siRNA. 
qRT-PCR analysis showed that the expression level of TNF-α mRNA was 
significantly increased in scrambled siRNA (negative control) transfected BV-2 
microglia cells exposed to LPS in comparison to cells transfected with negative 
control siRNA. However, following knockdown of Dpysl3, the LPS-induced 
increase in the expression of TNF-α mRNA was markedly attenuated as compared 
to the scrambled siRNA control (Fig.9A). Immunofluorescence analysis revealed 
a similar trend in the expression of TNF-α in LPS activated BV-2 microglia 
following knockdown of Dpysl3 (Fig.9B-E). The western blot further confirms 
that knockdown of Dpysl3 prevents the LPS-induced increase in expression of 





3.4.3 Knockdown of  Dpysl3 decreases the production of IL-1β cytokine by 
activated microglia 
qRT-PCR analysis showed that the mRNA expression level of IL-1β was 
upregulated in scrambled siRNA transfected BV-2 microglial cells exposed to 
LPS in comparison to negative control siRNA transfected cells. Knockdown of 
Dpysl3 decreased the expression IL-1β mRNA in LPS activated cells when 
compared to the control. (Fig.10A). This expression pattern was also observed in 
the intensity of IL-1β immunofluorescence in LPS activated microglia following 
knockdown of Dpysl3 (Fig.10B-E). The results of western blot further confirmed 
that knockdown of Dpysl3 reduced the expression level of IL-1β protein in 
activated microglia as compared to the scrambled siRNA microglial cells 
(Fig.10F,G). 
3.4.4 Knockdown of  Dpysl3 reduces the expression of iNOS expression in 
activated microglia 
qRT-PCR analysis revealed that the mRNA expression of iNOS was increased in 
LPS treated BV-2 microglia, whereas knockdown of Dpysl3 significantly 
decreased the mRNA expression of iNOS in activated BV-2 microglial by LPS as 
compared to  scrambled siRNA cells exposed to LPS (Fig.11A). In addition, this 






3.4.5 Knockdown of  Dpysl3 reduces production of nitric oxide in activated 
microglia 
The amount of nitric oxide (NO) produced by microglial cells was measured in 
the medium obtained from BV-2 microglial cultures subjected to LPS treatment 
following siRNA transfection. The concentration of  NO  in scrambled siRNA 
transfected BV-2 microglial cells was observed to be increased after 1h of LPS 
stimulation. However, knockdown of Dpysl3 significantly reduced the induction 
of NO production by activated microglia (Fig.12). 
3.4.6 Knockdown of  Dpysl3 suppresses NF-κB transcriptional activity 
Activation of NF-κB activation is associated with microglial activation. NF-
κB is an important transcription factor that regulates genes encoding 
proinflammatory cytokines, chemokines, and growth factors, thereby 
contributing to immune and inflammatory reaction (Meffert and Baltimore, 
2005). NF-κB was localized in the cytoplasm of BV-2 microglia transfected 
with scrambled siRNA and Dpysl3 siRNA (Fig.13A, B). In activated BV-2 
microglia by LPS, the nuclear translocation of NF-κB was evident (Fig.13C). 
However, knockdown of Dpysl3 markedly inhibited the NF-κB nuclear 
translocation in activated BV-2 microglia by LPS (Fig.13D). Western blot 
analysis using the nuclear protein derived from activated BV-2 microglia by 
LPS further confirmed that the knockdown of Dpysl3 significantly decreased 





(Fig.13E, F). The cytoplasmic NFkB shows no obvious change in its protein 
level as compared with nuclear NFkB (Data not shown). 
3.5 Dpysl3 regulates F-actin cytoskeleton, migration, phagocytosis and 
proliferation of microglia 
3.5.1 Knockdown of Dpysl3 alters the structure of F-actin organization 
Phalloidin labeling revealed that Dpysl3 colocalizes with F-actin cytoskeleton in 
BV-2 microglia (Fig 14A-C) and hence the organization of F-actin in BV-2 
microglia following knockdown of Dpysl3 was examined. The 
immunofluorescence staining in BV-2 microglia transfected with scrambled 
siRNA showed that the expression of Dpysl3 colocalized with F-actin which is 
associated with an orderly disturbed actin bundles (Fig.14A-C). Activated BV-2 
microglia by LPS exhibit microspike projections with intense staining of F-actin 
with Dpysl3 (Fig.14D-F). The siRNA-mediated knockdown of Dpysl3 drastically 
reduced the immunoexpression of Dpysl3 in BV-2 microglia (Fig.14G-L). 
Further, knockdown of Dpysl3 inhibited the formation of microspike projections 
and reduced the actin staining intensity in activated BV-2 microglia when 
compared to that of activated microglia transfected with scrambled siRNA 
(Fig.14J-L). The quantitative analysis showed that the siRNA mediated 
knockdown of Dpysl3 reduced the expression of Dpysl3 protein in BV-2 
microglia, in comparison to that of cells transfected with scrambled siRNA 
(Fig.14M). This experiment revealed that knockdown of Dpysl3 disturbed the 
arrangement of F-actin in microglial cells suggesting that Dpysl3 plays an 





3.5.2 Knockdown of Dpysl3 inhibits migration of microglia 
Since Dpysl3 appears to be involved in F-actin cytoskeleton organization, its role 
in cell migration was assessed by the transwell migration assay. For chemotaxis, 
LPS was added to the bottom of the chamber (Kim et al., 2006a; Karlstetter et al., 
2011) and the optimal time for cells to be activated and to migrate towards LPS in 
the bottom chamber were determined. Migration of BV-2 microglia transfected 
with scrambled siRNA was significantly increased towards the lower well 
containing medium with LPS (Fig.15C) when compared to that of BV-2 microglia 
transfected with scrambled siRNA or Dpysl3 siRNA (Fig 15A, B). However, 
siRNA-mediated knockdown of Dpysl3 reduced the chemotactic migrating 
capability of activated BV-2 microglia (Fig.15D, E). These results indicate that 
Dpysl3 regulates the migratory ability of microglia. 
3.5.3 Knockdown of Dpysl3 inhibits phagocytic ability of microglia 
To investigate the role of Dpysl3 in promoting microglial phagocytosis, the 
uptake of latex beads by microglia was assessed in vitro (Marker et al., 2012). 
The results of this assay showed that in unstimulated BV-2 microglial cells 
transfected with scrambled siRNA and Dpysl3 siRNA, only a small percentage of 
cells ingested with latex beads (Fig.16A, B). After LPS stimulation, the number of 
phagocytic cells laden with latex beads was significantly increased (Fig.16C, E). 
However in cells transfected with Dpysl3 siRNA treated with LPS significantly 
inhibited the latex beads adsorption (Fig.16D, E) suggesting that Dpysl3 





3.5.4 Knockdown of Dpysl3 reduces the proliferation of activated microglia 
CRMPs proteins have been shown to affect the proliferation index, and hence the 
role of Dpysl3 in proliferation of microglia was studied by the BrdU incorporation 
assay (Lehner et al., 2011). The LPS treatment increased the number of BrdU 
positive BV-2 microglia transfected with scrambled siRNA (Fig.17D-F) in 
comparison to that of scrambled siRNA transfected cells (Fig 17A-C). However 
knockdown of Dpysl3 reduced the proliferation index in activated microglia by 
LPS (Fig.17J-L, M). In addition to this, the BV-2 cells were labeled with 
microglia marker lectin (Fig.17A, D, G, J).  
3.6 Interaction of Dpysl3with Rho GTPases 
3.6.1 Interaction of Dpysl3 with RhoA 
Studies have reported that Dpysl3 interacts with Rho GTPases (namely, RhoA 
and Rac1)(Alabed et al., 2007)which are necessary for cytoskeletal organization 
and help in the process of cell migration (Van Aelst and D'Souza-Schorey, 1997; 
Barcia et al., 2012). RhoA pathway plays a prominent role in mediating the 
inflammatory and oxidative responses in microglia (Villar-Cheda et al., 2012). 
The interaction of Dpysl3 and RhoA was examined in microglia by co-
immunoprecpitation. Western blot result shows the  protein expression of Dpysl3 
and RhoA in BV-2 microglia before and after precipitation (Fig.18). Dpysl3 and 
RhoA co-immunoprecpitation was observed in control as well as LPS treated 
microglia. Microglia immunoprecipitated with isotype G was used as control to 





3.6.1.1 Knockdown of Dpysl3 reduces RhoA in activated microglia 
Interaction of Dpysl3 with Rho A has been demonstrated in neurons (Alabed et 
al., 2007). qRT-PCR results showed that mRNA expression of RhoA was 
increased upon LPS treatement to  BV-2  cells transfected with scrambled siRNA. 
However in cells transfected with Dpysl3 siRNA treated with LPS, the RhoA 
expression was significantly attenuated in BV-2 microglial cells transfected with 
Dpysl3 siRNA (Fig.19A). A similar pattern of decreased intensity of RhoA 
expression was observed in Dpysl3 siRNA transfected BV-2 cells (Fig.19B-E). 
The western blot result also confirmed a significant reduction in RhoA protein 
expression in LPS-activated BV-2 microglia transfected with Dpysl3 siRNA as 
compared to negative control (Fig.19 F, G). 
3.6.2 Interaction of Dpysl3 with Rac1 
Rac1 signaling in microglia promotes NADPH oxidase for the formation of 
reactive oxygen species (Gao et al., 2003; Zhang et al., 2012). Rac1 activation 
promotes microglial phagocytosis (Wilkinson et al., 2006). The interaction of 
Dpysl3 and Rac1 was observed in microglia by co-immunoprecpitation. Western 
blot result indicates the protein expression of Dpysl3 and Rac1 in BV-2 microglia 
before and after precipitation (Fig.20). Dpysl3 and Rac1 co-immunoprecpitation 
was detected in both control and LPS treated microglial cells. The microglia 
immunoprecipitated with isotype G was used as control for confirmation. 





Dpysl3 interaction with Rac1 was confirmed by co-immunoprecpitation. The 
Rac1 expression was also examined in BV-2 cells transfected with Dpysl3 
siRNA. qRT-PCR results showed a significant decrease in mRNA expression of 
Rac1 upon LPS treatement to  the  cells transfected with Dpysl3 siRNA compared 
to that of activated microglia transfected with scrambled siRNA (negative control) 
(Fig.21A). Immunofluorescence analysis also showed the similar pattern of 
intensity of Rac1expression in activated BV-2 microglia transfected with Dpysl3 
siRNA (Fig.21B-E). The western blot results further confirmed that the protein 
expression of Rac1 was significantly reduced in activated BV-2 microglia 
transfected with Dpysl3 siRNA compared to that of scrambled siRNA transfected 


























Activation of microglia is characterized with altered morphology extensive 
proliferation, chemotaxis, migratory behavior, and phagocytic ability in several 
neurodegenerative disorders and neuropathological conditions (Chamak and 
Mallat, 1991; Nolte et al., 1996; Guillemin and Brew, 2004; Dheen et al., 2007). 
Many of these processes in activated microglia are interrelated and involve 
dynamic reorganization of the actin cytoskeleton (Cross and Woodroofe, 1999; 
Martin et al., 2003), morphological changes, and lamellipodia projections which 
are  important in the initiation of cell migration (Lauffenburger and Horwitz, 
1996; Mitchison and Cramer, 1996). In addition, it has been reported that 
activated microglia in neonatal rats following hypoxia mediate the release of pro-
inflammatory cytokines, nitric oxide and free radicals (Deng et al., 2008).  
Controlling or inhibiting microglial activation is considered to be the primary 
therapeutic option in neurodegenerative disorders. Understanding the role of a 
cytoskeletal gene, Dpysl3 in regulating the function of activated microglia was the 
primary focus of this present study. 
4.1 Dpysl3 is developmentally regulated in microglia 
The function of Dpysl3 is well documented in neurogenesis and regeneration 
mediated by Semaphorin 3A / PlexinA signaling (Goshima et al., 1995; Nacher et 
al., 2002; Alabed et al., 2007). However the expression and role of Dpysl3 in 
microglia has remained unexplored. The present study convincingly demonstrated 
that Dpysl3 is developmentally regulated in microglia as it was found to be 
expressed in amoeboid microglial cells in postnatal rat brain from 3-day to 5-day 





microglial cells in the developing brain have been reported to phagocytose 
apoptotic cells, cellular debris and dying  neurons (Eyo and Dailey, 2013). The 
high expression of Dpysl3 in amoeboid microglia in early postnatal rat brain may 
be associated in rearrangement of microglial cytoskeleton in mediating the 
process of phagocytosis and migration in the developing brain. 
4.2 Dpysl3 expression increases in activated microglia in vitro and  in vivo 
Activated microglial cells are involved in inflammatory processes in the CNS and 
have been described in several neurodegenerative disorders. The microglial 
activation in response to neurological diseases namely Alzheimer’s , Parkinson’s 
disease or LPS has been shown to be associated with excessive production of pro-
inflammatory cytokines including IL-1β, TNF-α, IL-6 (Lund et al., 2006a) and 
neurotoxic mediators such as NO and ROS.  
LPS has been widely shown to activate microglia and mediate neurotoxic 
effects in both in vitro and in vivo system (Nakamura et al., 1999; Tanaka et al., 
2006). In macrophages and microglia, studies have described that binding of LPS 
to TLR4 receptors triggers the signaling cascades resulting in phosphorylation of 
NF-κB thereby play a key role in mediating inflammation in these cells (Sakurai 
et al., 1999). In this study, Dpysl3 expression was found to be induced in LPS-





4.3 Dpysl3 knockdown attenuated the production of proinflammatory 
cytokines and inflammatory mediators in activated BV-2 microglia 
Microglial activation is necessary for host defense and over activation of 
microglia is neurotoxic as reported in several neurodegenerative disorders 
(McGeer et al., 2005).  Therefore, we have studied the effect of knockdown of 
Dpysl3on proinflammatory cytokines and neurotoxic mediators generated by 
activated microglial cells. Neuroinflammation occurs in response to injury or 
infection or noxious stimuli in the CNS thereby leading to multiple 
neurodegenerative diseases (Wilms et al., 2007). Microglia, as the resident innate 
immune cells in the brain, actively monitor the microenvironment in the brain and 
are activated in response to diverse cues to produce proinflammatory cytokines 
namely TNF-α  and IL-1β  (Sawada et al., 1989) cytotoxic molecules such as 
reactive oxygen/nitrogen intermediates including ROS (Colton and Gilbert, 1987) 
and NO (Liu et al., 2002).  In the present study, knockdown of Dpysl3 in BV-2 
microglia significantly suppressed the LPS-induced protein levels of 
proinflammatory cytokines, IL-1β and TNF-α, suggesting that Dpysl3 could be an 
important mediator for cytokine production in activated microglial cells. The 
downregulation of Dpysl3 may lead to an effective inhibition of microglial 
activation and  cytokine production. 
iNOS catalyzes the production of nitric oxide (NO) which, acts as a 
neurotransmitter in the CNS and has protective functions in anti-inflammatory 
pathways (Possel et al., 2000). However, high concentrations of NO results in cell 





present study, Dpysl3 knockdown resulted in decreased iNOS expression and NO 
production in  activated microglial cells. In the light of this, it is suggested that 
Dpysl3 is linked to increased iNOS expression and subsequent NO release in 
microglia. 
4.4 NF-κB pathway is involved in Dpysl3 mediated microglial activation 
NF-κB is an important transcription factor shown to regulate genes involved in 
diverse functions including inflammation and immune responses. Under normal 
conditions, NF-κB is in an inactive state and is localized in the cytoplasm (Rhoads 
et al., 2010; Schuster et al., 2013). The NF-κB in pathological conditions is 
phosphorylated and translocates to the nucleus whereby it mediates the expression 
and regulation of pro-inflammatory genes (namely TNF-α and IL-1β), 
chemokines and growth factors in activated microglia (Viatour et al., 2005). In 
activated microglia, the NF-kB is transcriptionally activated and translocated to 
nucleus mediating the inflammatory response (Meffert and Baltimore, 2005; Shen 
et al., 2005; Baker et al., 2011).The present study demonstrated that knockdown 
of Dpysl3 significantly inhibits the LPS-induced transcriptional activity of NF-κB 
in BV-2 microglia, suggesting that Dpysl3 regulates NF-κB activity which may 
alter the inflammatory response of activated microglia. The present study shows 
that NF-κB as one of the downstream pathways involved in Dpysl3-induced 
production of inflammatory mediators. Overall, these results suggest that 
downregulation of Dpysl3 inhibits microglial activation and subsequent 
inflammation by preventing the production of proinflammatory cytokines and the 





4.5 Dpysl3 regulates cytoskeletal dynamics in activated microglia 
The process of migration is regulated by changes in the organization of actin and 
tubulin cytoskeletal proteins in microglia (Eugenin et al., 2005; Stricker et al., 
2010; Vincent et al., 2012). The cytoskeletal architecture consists of microtubules 
in central domain and F-actin in the peripheral domain. During the migration, the 
tubules invade from central to peripheral domain along with the actin rich 
lamellar region (Chhabra and Higgs, 2007)  thereby mediating the cell movement.  
LPS not only activates genes responsible for production of cytokines but it 
also causes marked changes in the morphological and cytoskeletal organization of 
microglia (abd-el-Basset and Fedoroff, 1995). Activation of microglia includes 
changes in cell shape, proliferation, migration and phagocytosis and is regulated 
by the organization of F-actin cytoskeleton. Regulation of F-actin dynamics is 
important for the cell motility processes (Lambrechts et al., 2004; Lippman et al., 
2008). Actin polymerization and depolymerization is involved in maintaining cell 
morphology and cell survival (Friedl, 2004). Dpysl3 has been widely shown to 
regulate cytoskeletal dynamics and F-actin bundling, which is essential for the 
cell motility process (Rosslenbroich et al., 2005). In neurons, overexpression of 
Dpysl3 has been shown to result in the extension of filopodia and neurite 
branches (Alabed et al., 2007). In the present study, Dpysl3 was localized with F-
actin and its expression was increased along the microspike projections of 
activated microglia. In addition, the knockdown of Dpysl3 appeared to inhibit the 





importance of Dpysl3 in regulating actin cytoskeleton in microglia and their 
migration when activated. 
4.6 Dpysl3 knockdown reduces microglial migration 
Activated microglia migrate to the site of injury or infection in the CNS 
(Blinzinger and Kreutzberg, 1968; Banati et al., 1993) and their migration  
process is regulated by organization of actin cytoskeleton  (Stence et al., 2001; 
Saraswathy et al., 2006).The present study has also shown that knockdown of 
Dpysl3 significantly perturbed the actin dynamics and the migration ability of 
activated microglia indicating that Dpysl3 promotes migration of activated 
microglia by regulating their cytoskeletal dynamics. This finding is significant as 
it may provide a functional basis for designing specific therapeutic strategy to 
delay or control migration of microglia to the site of injury or infection.  
4.7 Dpysl3 knockdown reduces microglial proliferation 
Microglia have the capacity to increase their cell numbers upon injury in CNS and 
in neurological diseases (Kettenmann et al., 2011). The microglial proliferation 
contributes to brain repair and functional recovery through inflammatory response 
and phagocytosis. However, excessive proliferation has been shown to be 
detrimental in chronic neurodegenerative disease producing cytotoxic molecules. . 
Dpysl3  has been shown to be associated with proliferation in neurons (Lin and 
Hsueh, 2008). However, the present study demonstrated that Dpysl3 is involved 
in the proliferation of microglia showing that knockdown of Dpysl3 resulted in 





4.8 Dpysl3 knockdown reduces the phagocytic activity of activated microglia 
In addition to motility and migration, actin remodeling has been shown to be 
critical for efficacy of phagocytosis and antigen presentation in immune cells 
(Abd-el-Basset and Fedoroff, 1994; Smith et al., 1998). Phagocytosis is a process 
which is initiated by attachment of particle bound ligands to phagocytic cell 
surface receptors (Guzman-Beltran et al., 2012). These receptors trigger signaling 
proteins at the particle binding site resulting in reorganization of actin 
cytoskeleton for particle ingestion (Gitik et al., 2010). Activated microglia show 
enhanced phagocytic function  in vitro and in vivo (Smith et al., 1998; Neher et 
al., 2011)and have been shown to engulf substances, including latex beads, E.coli, 
α2 macro-globulin, fluorescent labeled liposomes, zymosan in vitro (Smith, 2001; 
Kaur et al., 2004). It is possible that Dpysl3 mediates phagocytosis ability of 
microglia as it regulates actin dynamics. 
In the present study, the Dpysl3 knockdown significantly inhibited the 
phagocytic ability of activated microglia, thus strengthening the notion that 
Dpysl3 mediates phagocytic activity of the microglia by regulating the 
cytoskeletal dynamics. It should be noted that phagocytic function of microglia is 
not only regulated by Dpysl3 but also by pro-inflammatory cytokines such as 
TNF-α, IL-1β  and Il-6 (Cannella and Raine, 1995) and NO (Tumer et al., 2007). 
It is also possible that Dpysl3 may influence the phagocytic function of activated 
microglia by altering the production of proinflammatory cytokines and neurotoxic 





 The molecular mechanisms involved in microglial phagocytosis are 
largely unknown. Recent studies have indicated the importance of Rho-GTP 
binding proteins in phagocytosis activity (Caron and Hall, 1998; Coleman and 
Olson, 2002; Niedergang and Chavrier, 2005). 
4.9 Rho GTPases: RhoA and Rac1 pathways are involved in Dpysl3 mediated 
microglial activation 
The reorganization of actin cytoskeleton is essential for morphogenesis, 
phagocytosis and cell movement. It has been shown that actin remodeling is 
regulated by Rho family of small GTPases (Hall, 1998). Rho GTPases regulate 
several cellular events such as cytoskeletal organization, intracellular signaling 
and membrane trafficking in macrophages (Allen et al., 1997). These proteins 
have also been shown to be involved in mediating immune response by regulating 
phagocytosis, cytokine release, and production of ROS in leukocytes (Bokoch, 
2005, 2009; Sprague and Khalil, 2009). In the present study, knockdown of 
Dpysl3 markedly perturbed the actin cytoskeleton of microglia, indicating that the 
impairment of actin reorganization in microglia by Dpysl3 knockdown may be 
mediated via Rho GTPase signaling. 
4.9.1 RhoA in Dpysl3 mediated microglial activation 
RhoA pathway is involved in mediating the inflammatory and oxidative responses 
in microglia (Villar-Cheda et al., 2012). It has been shown that interaction of 
Dpysl3 with RhoA mediates inhibition of neurite outgrowth, thereby inducing 





2007). The present study showed that Dpysl3 interacts with RhoA in microglia 
and further knockdown of Dpysl3 decreases the mRNA and protein expression of 
RhoA in activated microglia. This inhibition of RhoA appears to be associated 
with impaired actin reorganization and migratory behavior of microglia. Overall, 
the present study suggests that interaction of Dpysl3 with RhoA regulates the 
cytoskeletal organization and migration of activated microglia. 
4.9.2 Rac1in Dpysl3 mediated microglial activation 
Rac1 is a member of Rho family small G-proteins, acts as a multifunctional 
molecular switch for generation of radicals, actin cytoskeleton and activation of 
transcription factors (Kitamura et al., 2003; Saraswathy et al., 2006; Grommes et 
al., 2008). Activation of Rac1 is known to promote lamellipodia and membrane 
ruffles (Ohsawa et al., 2000). Rac1 is shown to be involved in reorganization of 
actin cytoskeleton and plays a key role in microglial activation (Chung et al., 
2000). In addition, Rac1 signaling induces NADPH oxidase resulting in the 
formation of iNOS and ROS (Apolloni et al., 2013) and also induces microglial 
phagocytosis (Grommes et al., 2008). The present study showed that Rac1 
interacts with Dpysl3and knockdown of Dpysl3 in activated microglia reduced the 
expression of Rac1. The lack of Rac1 activation could result in attenuation of 
phagocytic activity and production of iNOS and ROS in activated microglia as 
observed after Dpysl3 knockdown.  
Overall, the present study demonstrated the mechanism by which Dpysl3 





developmentally regulated in microglia specifically expressed in the amoeboid 
microglia of the early postnatal rat brain and its expression is increased in 
activated microglial cells. Dpysl3is colocalized with F-actin cytoskeleton which is 
reorganized by the knockdown of Dpysl3. Further, Dpysl3 knockdown altered the 
expression of proinflammatory cytokines namely TNF-α and IL-1β and 
inflammatory mediators including iNOS and NO and the migratory and 
phagocytic capability of activated microglia, possibly by regulating NF-κB and 
Rho GTPases signaling pathways. From the present findings, it is suggested that 
Dpysl3 could be considered as a potential therapeutic target that may limit the 
neuroinflammatory response of microglia in neurodegenerative diseases.

























Neuroinflammation, which is a process by which the CNS responds to injury, 
infection and ischemia, has been shown to have both beneficial and detrimental 
effects on the CNS. However, chronic neuroinflammation is deleterious to 
neurological functions, leading to the pathogenesis of neurological diseases such 
as AD, PD, ALS, prion disease, epilepsy etc (Eikelenboom et al., 2006; Whitton, 
2007). But, the mechanisms by which it contributes to these pathological 
processes remain to be elucidated. It has been widely established that microglia, 
are the immune cells present in the CNS which respond to neuroinflammation and 
contribute to the disease processes. Hence it is clear that the study of microglial 
functions would provide new insights into neuroinflammation and pathogenesis of 
various neurological disorders. 
In CNS inflammation and diseases, microglia becomes activated, 
engulfing pathogens, dead cells, misfolded proteins and damaged synapses. 
Microglial activation is associated with its rapid proliferation, migration, 
phagocytic ability and morphological transformation and has been shown to be 
regulated by several intrinsic and extrinsic factors (Parakalan et al., 2012; 
Kierdorf and Prinz, 2013). Dysregulation of these factors may induce severe 
functional changes in the microglia, which could potentially result in 
neuropathological changes in the CNS. 
Recent transcriptome profiling studies revealed that several signaling 
molecules and transcription factors are differentially expressed in amoeboid and 




resting microglia indicating that these cells are functionally distinct (Parakalan et 
al., 2012). Further, several groups including our group have shown that microglial 
activation in neuropathological condition is regulated by several signaling 
molecules such as NF-κB, MAPKs, and SphK1 and transcription factors such as 
Runx1 and is inhibited by several drugs and factors including dexamethasone, 
retinoic acid, melatonin, N,N-dimethylsphingosine (DMS) etc (Dheen et al., 2005; 
Zhou et al., 2007; Gao et al., 2010a; Nayak et al., 2010; Huo et al., 2011). 
However, these drugs and factors not only target microglia, but also target various 
other cell types, leading to unwanted side effects. Hence identification of factors 
regulating the microglial activation is of paramount importance.  
Dihydropyrimidinase-like protein 3 (Dpysl3) has been shown to play 
important roles in neuronal differentiation, axonal outgrowth and neuronal 
regeneration (Goshima et al., 1995) and also involved in axon injury (Alabed et 
al., 2007). Interestingly, our studies revealed that Dpysl3 is highly expressed in 
amoeboid microglia and its expression is induced in activated microglia 
(Parakalan et al., 2012; Manivannan et al., 2013). Further, it appears to play an 
important role in microglia-mediated neuroinflammation by altering microglial 
cell proliferation, migration, phagocytic ability, secretory activity and 
morphology through NF-κB and Rho GTPase pathways and actin cytoskeleton 
derangement (Figure IV). 
Overall, these findings provide a functional basis for designing specific 
therapeutic strategy to control microglial migration to the injured site and 
subsequently to inhibit microglia-mediated neuroinflammation. Moreover, this 




study describes that Dpysl3 not only functions as a cytoskeletal gene but also acts 
as a novel regulator for inflammatory response, migration and phagocytosis of 
activated microglia.  
Although this study demonstrates the potential function of Dpysl3 in 
activated microglia, further studies using in vivo animal models such as Dpysl3 
knockout mice, AD mice and TBI mice, would be required to understand its 
functions in neuropathological conditions. 
 
Figure IV: An illustration demonstrates the functional events of 
Dihydropyrimidinaselike-3 in activated microglia. siRNA knockdown of 
Dpysl3inhibits microglial activation, migration, proliferation and phagocytic 
capability by suppressing the release of proinflammatory mediators via NF-κB 
signaling. Further Dpysl3 knockdown alters the F-actin structure and decreases 
the Rho GTPase proteins namely RhoA and Rac1 in activated microglia. 
 




5.2 Scope for future studies 
1. Activation of microglia has been associated with various neurodegenerative 
diseases. Hence, suppression of  microglia-mediated inflammation  is considered 
to be therapeutic strategy in several neurodegenerative disorders.While majority 
of studies have focused on the regulation of the production of cytokines and 
neurotoxic mediators by activated microglia,the study on regulation of 
cytoskeleton organization inactivated microglia is only minimal. Therefore there 
is good scope for further investigations to validate the Dpysl3 role on cytoskeletal 
reorganization in activated microglia using the Dpysl3 knockout mice model. 
2. In order to investigate Dpysl3 as a therapeutic target, future studies using 
transgenic/ knockout animal models of Dpysl3 will be required to elucidate the 
exact mechanisms which Dpysl3 inhibit ablate toxic functions (such as excessive 
production of pro-inflammatory cytokines) while retaining protective functions 
(such as migration to the injury site and phagocytic clearance of cell debris) of 
activated microglia in neuropathological conditions. 
3. Recently, miRNA-132 has been shown to regulate the Dpysl3 in schizophrenic 
patients (Miller et al., 2012) and to promote inflammation by targeting NF-κB. 
Future study can investigate if miRNA-132 is expressed in microglia and if it 
modulates microglia-mediated inflammatory response by regulating Dpysl3. 
Moreover, epigenetic regulation of Dpysl3 in activated microglia may also be 
investigated in detail. 




4. The present study has investigated the effects of Dpysl3 knockdown on 
microglial activation. Dpysl3 functions in activated microglia can be further 
established by overexpressing this gene in microglia. 
5. This study has investigated the role of Dpysl3 in microglia after LPS-induced 
inflammation in the rat pups. There is a tremendous scope to extend similar 
studies in animal models of neurological disorders such as AD, PD, TBI, etc., to 
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Fig.1.A. Confocal image shows the OX42 (green) microglia in the corpus 
callosum (CC, within dotted lines) in the postnatal rat brain.  B. Confocal 
image with higher magnification shows the OX42 stained microglia in regions of 
corpus callosum (CC), lateral ventricle (LV) and subventricular zone (SVZ).  
(CX indicates cortex region).





























Fig.2. Differential immunoexpression of Dpysl3 in AMC and RMC. A. 
Confocal image showing the corpus collasum in 5-day postnatal rat brain. (CC-
corpus callosum, SVZ- subventricular zone). Confocal images show the 
immunoexpression of Dpysl3 (red in C, F, I) and OX42 (green in B, E, H) in 
amoeboid microglial cells (AMC) in the corpus callosum (arrows). Colocalization 
of OX42 and Dpysl3 is shown in merged images (yellow in D, G, J). Dpysl3 
expression is evident at postnatal day 3, 5 and 7-day and is absent in the RMC of 
postnatal day 14 (red in L). Nuclei are stained with DAPI (blue). Scale bar: 
200μm & 50μm. N) The quantitative analysis shows that the percentage of 
Dpysl3-positive microglial cells in the corpus callosum decreases gradually with 
advancing age.  The number of Dpysl3 positive cells decreased in the corpus 






















































Fig. 3. Co-localization of Dpysl3 and OX42 in the LPS-treated postnatal rat 
brain by double fluorescence labeling. A–C) In normal postnatal rat brain (5-
day old), Dpysl3 expression (red) is localized in OX42-positive microglial cells 
(green, arrows). D-F) Dpysl3 expression (red in E) appears to be increased in 
OX42 positive microglia (arrows) in the corpus callosum of postnatal rat pups 
injected with LPS. (CC-corpus callosum, SVZ- subventricular zone). Sections are 
counterstained with DAPI (blue). Scale bar: 100μm. G) The quantitative analysis 
shows that the percentage of Dpysl3-postive AMC is increased in the corpus 
callosum of LPS injected 5-day old rats when compared to the control. Data are 
































Fig.4. Dpysl3 expression in microglial cells of the LPS-treated mature rat 
brain. A-C) In the normal mature rat brain (28-day old), the expression of Dpysl3 
(red in B) is undetectable in OX42-positive (green) microglial cells (arrows in A). 
D-F) The expression of Dpysl3appears to be induced in OX42-positive microglia 
(arrows) in the corpus callosum of mature rats after LPS injection. Sections are 
counterstained with DAPI (blue). Scale bar: 50μm. G) The quantitative analysis 
shows that the percentage of Dpysl3-postive microglia is significantly increased 
in the corpus callosum of LPS-injected 28 day rats when compared to the control. 



































Fig.5. Expression of Dpysl3 in the rat primary microglia. A-F) Confocal 
images show that the expression of Dpysl3 is highly increased in (red, E) in 
primary microglia treated with LPS when compared to the control (B). Lectin 
(green) is used as a marker for microglia.  Nucleus is stained with DAPI (blue). 



































Fig.6. Dpysl3 expression level is increased in BV-2 microglia treated with 
LPS. A) The quantitative RT-PCR analysis shows that mRNA expression of 
Dpysl3 was upregulated at 1h after LPS treatment and gradually reduced at 6h 
after LPS exposure. Data are presented as mean ± SD (n=4), **p<0.01; *p<0.05. 
(B) Gel image showing the size of the amplicons (225bp). C-F) Confocal images 
show that expression of Dpysl3 (red in D) is increased in BV-2 microglia (arrows) 
at 1h after LPS treatment and is progressively decreased at 3h and 6h after LPS 
treatments (red in C, D). Scale bar: 50μm. G) Representative western blot 
showing the expression of Dpysl3 (65kDa) and β-actin (42kDa). H) Quantitative 
analysis confirms that the expression of Dpysl3 protein peaks at 1h but is reduced 
to basal level at 3-6h after LPS treatment. Data are represented as mean ± SD 




























































Fig. 7. Distribution of Dpysl3 and F-actin in control and LPS-treated BV-2 
microglial cells. A-C) Confocal images show the colocalization of Dpysl3 with 
Phalloidin dye (a high-affinity F-actin probe conjugated to the red-fluorescent 
dye) in untreated and LPS-treated BV-2microglia. D-F) Increased 
immunostaining of both Dpysl3 (FITC, green) and F-actin (red) is evident in 


































Fig.8. siRNA-mediated knockdown of Dpysl3 gene in BV-2 microglial cells. 
A) The expression of Dpysl3 mRNA was analyzed in Dpysl3 siRNA-transfected 
BV-2 cells by RT-PCR. The knockdown efficiency of about 80% was obtained in 
Dpysl3siRNA transfected cells when compared to cells transfected with negative 
control (scrambled siRNA-transfected cells). Data are presented as mean ± SD 
(n=3),*p<0.05. B) The viability assay shows that about 87-93% of the cells were 
viable after siRNA transfection. Data are presented as mean ± SD (n=3). C) 
Dpysl3 (65kDa) and β-actin (42kDa) immunoreactive bands are shown. D) The 
quantitative analysis shows the siRNA-mediated knockdown of Dpysl3 reduced 
the endogenous expression of Dpysl3 protein in BV-2 microglia significantly in 
comparison to that of cells transfected with scrambled siRNA. Data are presented 

























































Fig. 9. Effect of Dpysl3 knockdown on the production of TNF-α in BV-2 
microglia. A) RT-PCR analysis shows that knockdown of Dpysl3 inhibits the 
expression of TNF-α mRNA in activated microglia at 1h LPS treatment, 
compared with that of negative control. Data are presented as mean ± SD (n=4), 
**p<0.01;*p<0.05. B-E) Immunofluorescence images show the upregulation in 
TNF-α expression in BV-2 microglial cells (arrows) treated with LPS while the 
knockdown of Dpysl3 inhibits the LPS-stimulated increase inDpysl3 expression 
(red, D, E) Scale bar: 50μm. F) Representative western blots showing the 
expression of TNF-α (25.6kDa) and β-actin (42kDa) in Dpysl3 knockdown cells. 
G) Quantitative analysis shows that the knockdown of Dpysl3 reduced the 
expression of TNF-α protein in activated microglia by LPS. Data are presented as 

































































Fig.10. Effect of Dpysl3 knockdown on the production of IL-1β in BV-2 
microglia. A) RT-PCR analysis shows that knockdown of Dpysl3 decreases the 
IL-1β mRNA expression in activated microglia following 1h LPS treatment, 
compared with that of negative controls. Data are presented as mean ± SD (n=4), 
**p<0.01;*p<0.05. B-E) Immunofluorescence images show the upregulation of 
IL-1β expression (red, C) in BV-2 microglial cells (arrows) treated with LPS and 
the knockdown of Dpysl3 inhibits the LPS-stimulated increase of Dpysl3 
expression (red, D, E). Scale bar: 50μm. F) IL-1β (17kDa) and β-actin (42kDa) 
immunoreactive bands are shown. G) Histogram shows that knockdown of 
Dpysl3 reduces the protein expression of IL-1β in BV-2 microglia treated with 




































































Fig. 11. Effect of Dpysl3 knockdown on the mRNA and protein expression of 
iNOS in activated BV-2 microglia. A) qRT-PCR analysis shows that 
knockdown of Dpysl3 decreases the induction of iNOS mRNA expression in 
activated microglia at 1h LPS treatment, compared with that of negative control. 
Data are presented as mean ± SD (n=4), where **p<0.01;*p<0.05. B-E) 
Immunofluorescence images show that the knockdown of Dpysl3 reduced the 















































Fig. 12. Effect of knockdown of Dpysl3 on the production of nitric oxide (NO) 
in activated BV-2 microglia. Bar graph shows that NO release was induced 
significantly in activated microglia while the knockdown of Dpysl3 inhibited this 
induction in activated microglia following 1h LPS treatment. Data are presented 












































Fig.13. Knockdown of Dpysl3 inhibits the nuclear translocation of NF-κB in 
activated BV-2 microglial cells. A-D) Confocal images of BV-2 microglia 
transfected with Dpysl3 siRNA or negative control and treated with or without 
LPS are shown. The nuclear translocation of NF-κB (red, arrows in C) is evident 
in activated BV-2 microglial cells following 1h LPS treatment. However, majority 
of the cells transfected with Dpysl3 siRNA did not show nuclear translocation of 
NF-κB (D). Nuclei are stained with DAPI (blue). Scale bar: 50μm. E) Western 
blot shows the expression of NF-κB (65kDa) and LaminA (74kDa) in nuclear 
protein isolated from the various groups of BV-2 microglial cells. F) The 
quantitative analysis revealed that the expression of nuclear NF-κB protein is 
increased in BV-2 cells exposed to LPS. However, this increase is not evident in 
activated BV-2 microglia following knockdown of Dpysl3, indicating a 
suppression of nuclear translocation of NF-κB protein. Data are presented as 
































Fig. 14. Confocal immunofluorescence images showing the expression of 
Dpysl3 (FITC, green) with F-actin (TRITC, red) in BV-2 microglial cells 
transfected with scrambled siRNA (A-F) and Dpysl3 specific siRNA (G-L). 
A-F) The expression of Dpysl3 which colocalizes with F-actin in negative control 
transfected BV-2 microglia cells (A-C) appear to be increased when the BV-2 
microglial cells were treated with 1h LPS (D-F). Note that microglia treated with 
LPS exhibit actin microspike projections (D-F); Knockdown of Dpysl3 resulted in 
reduced actin staining and formation of actin microspike projections (G-I) 
following LPS treatment compared to negative control (G-L). Scale bar: 20μm.M) 
Quantitative analysis shows that siRNA-mediated knockdown of Dpysl3 
decreased the intensity of Dpysl3 expression in BV-2 microglial cells, compared 





























































Fig. 15. Transwell migration assay shows that knockdown of Dpysl3 reduces 
the migration of activated BV-2 microglia. A-D) Light microscopy images of 
BV-2 cells transfected with Dpysl3 siRNA or negative control and treated with or 
without LPS in transwell chamber are shown. E) The quantitative analysis 
revealed an increase in migration of microglia, while knockdown of Dpysl3 
reduced the migrating ability of BV-2 microglia. Data are represented as mean ± 














































Fig. 16.Knockdown of Dpysl3 inhibits the phagocytosis by activated BV-2 
microglia. A-D) Confocal images of BV-2 microglial cells transfected with 
Dpysl3siRNA or negative control and treated with or without LPS are shown. 
Only a small percentage of unstimulated BV-2 microglial cells transfected either 
with scrambled or Dpysl3 siRNA, ingested with latex beads. E) The quantitative 
analysis shows the number of phagocytic cells laden with latex beads increased 
significantly after 1h LPS stimulation, while knockdown of Dpysl3 appears to 
inhibit this increase significantly. Data are presented as mean ± SD (n=4), 
















































Fig. 17. Effect of Dpysl3 knockdown on the proliferation index of BV-2 
microglia. A-L) Confocal immunofluorescence images showing the expression of 
BrdU (red) and lectin (green) in control and LPS-activated BV-2 microglia 
following transfection of Dpysl3 or scrambled siRNA. M) Quantitative analysis 
shows that the percentage of BrdU positive cells was significantly increased in 
scrambled siRNA transfected BV-2 microglial cells following 1h LPS 
stimulation. Knockdown of Dpysl3 significantly inhibited this increase in 
activated BV-2 microglial cells.  Data are presented as mean ± SD (n=6),*p<0.05. 


















































Fig.18.Interaction of Dpysl3 and RhoA by co-immunoprecipitation in 
microglial BV-2 cells. Western blot shows the expression of Dpysl3 and RhoA 
proteins in BV-2 microglia before and after immunoprecipitation. Dpysl3 (65kDa) 
and RhoA (24kDa) proteins were co-immunoprecipitated from control as well as 
in 1h LPS treated microglia. Mouse IgG was used as an isotype control. (Control-
Wild type: Untreated BV-2 cells, Control- IgG: IgG pull down from untreated 
BV-2 cells, Control- Ab: Antibody pull down from untreated BV-2cells, LPS- 
Wild type: LPS treated BV-2 cells, LPS- IgG: IgG pull down from LPS-treated 











































Fig.19. Effect of Dpysl3 knockdown on the production of  RhoA in activated 
BV-2 microglia. A) RT-PCR analysis shows that knockdown of Dpysl3 inhibits 
the expression of RhoA mRNA activated microglia at 1h LPS treatment, 
compared with that of negative control. Data are presented as mean ± SD (n=4), 
**p<0.01. B-E) Immunofluorescence images show the upregulation of  RhoA 
expression in BV-2 microglial cells treated with LPS, while the knockdown of 
Dpysl3 inhibits the LPS-stimulated increase in RhoA expression (red, E), Scale 
bar: 50μm. F) Representative western blot shows the expression of RhoA (24kDa) 
and β-actin (42kDa) proteins in scrambled or Dpysl3 siRNA transfected BV-2 
microglial cells. G) Quantitative analysis shows that knockdown of Dpysl3 
reduced the protein expression of RhoA in microglia treated with LPS. Data are 


































































Fig. 20. Interaction of Dpysl3 and Rac1 by co-immunoprecipitation in 
microglial BV-2 cells. Western blot shows the expression of Dpysl3 and Rac1 
proteins in BV-2 microglia before and after immunoprecpitation. Dpysl3 and 
Rac1 proteins were co-immunoprecipitated from the control as well as in 1h LPS 
treated microglia.  Mouse IgG was used as an isotype control. (Control-Wild 
type: Untreated BV-2 cells, Control- IgG: IgG pull down from untreated BV-2 
cells , Control- Ab: Antibody pull down from Untreated BV-2 cells, LPS- Wild 
type:LPS treated BV-2 cells, LPS- IgG: IgG pull down from LPS treated BV-2 









































Fig. 21.Effect of Dpysl3 knockdown on the production of Rac1 in activated 
microglia. A) RT-PCR analysis shows that knockdown of Dpysl3 inhibits the 
expression of Rac1 mRNA activated microglia following 1h LPS treatement, 
compared with that of negative control. Data are presented as mean ± SD (n=4), 
**p<0.01. B-E) Immunofluorescence images show the upregulation of Rac1 
expression in BV-2 microglial cells treated with LPS, while the knockdown of 
Dpysl3 inhibits the LPS-stimulated increase in RhoA expression (red, E), Scale 
bar: 50μm. F) Representative western blot shows the expression of Rac1 (21kDa) 
and β-actin (42kDa) proteins in scrambled or Dpysl3 siRNA transfected BV-2 
microglial cells. G) Quantitative analysis shows that knockdown of Dpysl3 
reduced the protein expression of Rac1 in microglia treated with LPS. Data are 
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